Part I. FINANCIAL INFORMATION Exhibit 99.1

Item 1. Financial Statements

MOLYCORP, INC.

Condensed Consolidated Balance Sheets (Unaudited)

(In thousands, except share and per share amounts)

	September 30, 2012		December 31, 2011
ASSETS
Current assets:
Cash and cash equivalents	$	436,025	$	418,855
Trade accounts receivable, net (Note 4)	88,471		70,679
Inventory (Note 5)	281,133		111,943
Deferred charges (Note 15)	12,517		7,318
Deferred tax assets (Note 15)	17,402		—
Income tax receivable	38,933		10,514
Prepaid expenses and other current assets	48,711		19,735
Total current assets	923,192		639,044
Non-current assets:
Deposits (Note 6)	23,287		23,286
Property, plant and equipment, net (Note 7)	1,363,444		561,628
Inventory (Note 5)	9,601		4,362
Intangible assets, net (Note 9)	479,173		3,072
Investments	68,006		20,000
Deferred tax assets (Note 15)	10,298		—
Goodwill (Note 11)	505,003		3,432
Other non-current assets	5,322		301
Total non-current assets	2,464,134		616,081
Total assets	$	3,387,326	$	1,255,125

1

	September 30, 2012			December 31, 2011
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Trade accounts payable	$	230,255		$	161,587
Accrued expenses (Note 12)	66,289			12,898
Income tax payable	25,601			—
Deferred tax liabilities (Note 15)	128			1,356
Debt and capital lease obligations (Note 14)	32,935			1,516
Other current liabilities	2,096			1,266
Total current liabilities	357,304			178,623
Non-current liabilities:
Asset retirement obligation (Note 13)	20,727			15,145
Deferred tax liabilities (Note 15)	189,894			18,899
Debt and capital lease obligations (Note 14)	1,183,528			196,545
Derivative liability (Note 25)	8,846			—
Pension liabilities	2,855			—
Other non-current liabilities	3,020			683
Total non-current liabilities	1,408,870			231,272
Total liabilities	$	1,766,174		$	409,895
Commitments and contingencies (Note 19)
Stockholders’ equity:
Common stock, $0.001 par value; 350,000,000 shares authorized at September 30, 2012 (Note 16)	138			84
Preferred stock, $0.001 par value; 5,000,000 shares authorized at September 30, 2012 (Note 16)	2			2
Additional paid-in capital	1,686,226			838,547
Accumulated other comprehensive loss	(9,646		)	(8,481		)
(Deficit) retained earnings	(74,898		)	15,078
Total Molycorp stockholders’ equity	1,601,822			845,230
Noncontrolling interests	19,330			—
Total stockholders’ equity	1,621,152			845,230
Total liabilities and stockholders’ equity	$	3,387,326		$	1,255,125

See accompanying notes to the condensed consolidated financial statements.

2

MOLYCORP, INC.

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)

(In thousands, except share and per share amounts)

	Three Months Ended						Nine Months Ended
	September 30						September 30
	2012			2011			2012			2011
Sales	$	205,604		$	138,050		$	394,651		$	263,927
Costs of sales:
Costs excluding depreciation and amortization	(184,128		)	(50,602		)	(337,769		)	(105,670		)
Depreciation and amortization	(10,612		)	(5,056		)	(19,065		)	(9,588		)
Gross profit	10,864			82,392			37,817			148,669
Operating expenses:
Selling, general and administrative	(31,468		)	(12,182		)	(78,721		)	(31,465		)
Corporate development	(1,073		)	(573		)	(19,379		)	(3,889		)
Depreciation, amortization and accretion	(9,723		)	(544		)	(12,361		)	(1,384		)
Research and development	(8,929		)	(2,148		)	(18,628		)	(5,165		)
Operating (loss) income	(40,329		)	66,945			(91,272		)	106,766
Other (expense) income:
Other expense	(57		)	(117		)	(37,615		)	(152		)
Foreign exchange gains (losses), net	1,910			(2,000		)	724			(1,850		)
Interest expense, net	(5,269		)	(671		)	(14,989		)	(461		)
	(3,416		)	(2,788		)	(51,880		)	(2,463		)
(Loss) income before income taxes and equity earnings	(43,745		)	64,157			(143,152		)	104,303
Income tax benefit (expense)	28,956			(19,056		)	58,442			(12,643		)
Equity in results of affiliates	(662		)	—			(1,146		)	—
Net (loss) income	(15,451		)	45,101			(85,856		)	91,660
Net (income) loss attributable to noncontrolling interest	(3,440		)	255			(4,120		)	(713		)
Net (loss) income attributable to Molycorp stockholders	$	(18,891	)	$	45,356		$	(89,976	)	$	90,947
Net (loss) income	$	(15,451	)	$	45,101		$	(85,856	)	$	91,660
Other comprehensive income:
Foreign currency translation adjustments	526			(5,564		)	(1,165		)	(4,240		)
Comprehensive (loss) income	$	(14,925	)	$	39,537		$	(87,021	)	$	87,420
Comprehensive (loss) income attributable to:
Molycorp stockholders	(11,485		)	40,346			(82,901		)	87,130
Noncontrolling interest	(3,440		)	(809		)	(4,120		)	290
	$	(14,925	)	$	39,537		$	(87,021	)	$	87,420
(Loss) income per share of common stock (Note 17):
Basic	$	(0.19	)	$	0.51		$	(0.97	)	$	1.01
Diluted	$	(0.19	)	$	0.49		$	(0.97	)	$	1.00

See accompanying notes to the condensed consolidated financial statements.

3

MOLYCORP, INC.

Condensed Consolidated Statement of Stockholders’ Equity (Unaudited)

(In thousands, except share and per share amounts)

	Common Stock				Series A Mandatory Convertible Preferred Stock			Additional Paid-In Capital			Accumulated Other Comprehensive Loss			Retained Earnings			Total Molycorp Stockholders' Equity			Non controlling interests			Total Stockholders' Equity
	Shares		$		Shares	$
Balance at December 31, 2011	83,896,043		$	84	2,070,000	$	2	$	838,547		$	(8,481	)	$	15,078		$	845,230		$	—		$	845,230
Stock-based compensation (Note 18)	(601	)	—		—	—		3,764			—			—			3,764			—			3,764
Issuance of shares for investment from Molymet, net of stock issuance costs (Note 16)	12,500,000		12		—	—		390,081			—			—			390,093			—			390,093
Issuance of shares for interest in Molycorp Canada (Note 16)	13,862,286		14		—	—		284,130			—			—			284,144			15,761			299,905
Component of convertible debt (Note 14)	—		—		—	—		71,801			—			—			71,801			—			71,801
Deferred taxes on component of convertible debt	—		—		—	—		(27,106		)	—			—			(27,106		)	—			(27,106		)
Issuance of shares for conversion of Debentures (Note 14)	99,723		—		—	—		1,421			—			—			1,421			—			1,421
Issuance of Primary Shares (Note 16)	13,800,000		14		—	—		132,116			—			—			132,130			—			132,130
Issuance of Borrowed Shares (Note 16)	13,800,000		14		—	—		11			—			—			25			—			25
Net (loss) income	—		—		—	—		—			—			(89,976		)	(89,976		)	4,120			(85,856		)
Preferred dividends	—		—		—	—		(8,539		)	—			—			(8,539		)	—			(8,539		)
Distribution to noncontrolling interests	—		—		—	—		—			—			—			—			(551		)	(551		)
Other comprehensive loss	—		—		—	—		—			(1,165		)	—			(1,165		)	—			(1,165		)
Balance at September 30, 2012	137,957,451		$	138	2,070,000	$	2	$	1,686,226		$	(9,646	)	$	(74,898	)	$	1,601,822		$	19,330		$	1,621,152

See accompanying notes to the condensed consolidated financial statements.

4

	Common Stock			Series A Mandatory Convertible Preferred Stock			Additional Paid-In Capital		Accumulated Other Comprehensive Loss			Retained Earnings			Total Molycorp Stockholders' Equity			Non controlling interests			Total Stockholders' Equity
	Shares	$		Shares	$
Balance at December 31, 2010	82,291,200	$	82	—	$	—	$	539,866	$	—		$	(93,435	)	$	446,513		$	—		$	446,513
Sale of Series A mandatory convertible preferred stock at $100.00 per share, net of underwriting fees and other offering costs	—	—		2,070,000	2		199,640		—			—			199,642			—			199,642
Stock-based compensation	11,570	—		—	—		4,042		—			—			4,042			—			4,042
Issuance of shares for interest in Molycorp Silmet	1,593,419	2		—	—		72,653		—			—			72,655			8,820			81,475
Component of convertible debt	—	—		—	—		36,227		—			—			36,227			—			36,227
Deferred taxes on component of convertible debt	—	—		—	—		13,437		—			—			13,437			—			13,437
Net income	—	—		—	—		—		—			90,947			90,947			713			91,660
Preferred dividends	—	—		—	—		—		—			(6,167		)	(6,167		)	—			(6,167		)
Other comprehensive loss	—	—		—	—		—		(3,817		)	—			(3,817		)	(423		)	(4,240		)
Balance at September 30, 2011	83,896,189	$	84	2,070,000	$	2	$	865,865	$	(3,817	)	$	(8,655	)	$	853,479		$	9,110		$	862,589

See accompanying notes to the condensed consolidated financial statements.

5

MOLYCORP, INC.

Condensed Consolidated Statements of Cash Flows (Unaudited)

(In thousands)

	Nine months ended
	September 30, 2012			September 30, 2011
Cash flows from operating activities:
Net (loss) income	$	(85,856	)	$	91,660
Adjustments to reconcile net (loss) income to net cash from operating activities:
Depreciation, amortization and accretion	31,426			10,972
Deferred income tax benefit	(35,179		)	(4,544		)
Inventory write-downs	41,082			1,585
Release of inventory step-up value	26,428			10,200
Stock-based compensation expense	3,179			4,042
Amortization of debt discount	1,257			1,037
Allowance for doubtful accounts	2,500			—
Other operating adjustments	56			2,461
Net change in operating assets and liabilities (Note 22)	(32,081		)	(88,689		)
Net cash (used in) provided by operating activities	(47,188		)	28,724
Cash flows from investing activities:
Cash paid in connection with acquisitions, net of cash acquired	(591,011		)	(20,021		)
Investment in joint venture	(28,130		)	—
Deposits	(516		)	2,946
Cash paid to acquire non-marketable securities	—			(20,000		)
Capital expenditures	(644,683		)	(160,917		)
Other investing activities	4,953			19
Net cash used in investing activities	(1,259,387		)	(197,973		)
Cash flows from financing activities:
Capital contributions	390,225			—
Repayments of short-term borrowings—related party	—			(2,343		)
Repayments of debt	(228,431		)	(5,447		)
Net proceeds from sale of preferred stock	—			199,642
Net proceeds from sale of common stock	132,471			—
Issuance of 10% Senior Secured Notes	635,373			—
Issuance of 6.00% Convertible Notes	395,712			—
Issuance of 3.25% Convertible Notes	—			223,100
Payments of preferred dividends	(8,539		)	(6,167		)
Proceeds from debt	9,456			6,337
Other financing activities	(3,331		)	—
Net cash provided by financing activities	1,322,936			415,122
Effect of exchange rate changes on cash	809			(348		)
Net change in cash and cash equivalents	17,170			245,525
Cash and cash equivalents at beginning of the period	418,855			316,430
Cash and cash equivalents at end of period	$	436,025		$	561,955

See accompanying notes to the condensed consolidated financial statements.

6

MOLYCORP, INC.

Notes to Condensed Consolidated Financial Statements

September 30, 2012

(Unaudited)

(1) Basis of Presentation

Molycorp, Inc. (“Molycorp” or the “Company”) is one of the world's leading rare earth products and rare metals companies. Molycorp owns: a world-class rare earth mine and processing facilities at Mountain Pass, California (the "Molycorp Mountain Pass facility"); Molycorp Silmet, one of the largest rare earth oxide ("REO") and rare metal producers in Europe; and the only producer of rare earth alloys in the United States, Molycorp Metals and Alloys ("MMA"). Following the acquisition of Neo Material Technologies, Inc. (formerly referred to as “Neo” and now Molycorp Minerals Canada ULC or “Molycorp Canada”) on June 11, 2012, Molycorp is currently a leading global producer of neodymium-iron-boron (“NdFeB”) magnetic powders (“Neo Powders”), which are used to manufacture bonded NdFeB permanent rare earth magnets, and a leading global manufacturer and distributor of rare earths and zirconium-based engineered materials and applications, and other rare metals and their compounds.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and Regulation S-X promulgated under the Securities Exchange Act of 1934 (the “Exchange Act”). While the December 31, 2011 balance sheet information was derived from the Company’s audited financial statements, for interim periods, GAAP and Regulation S-X do not require all information and related disclosures that are required in the annual financial statements, and all disclosures required by GAAP for annual financial statements have not been included. Therefore, the accompanying unaudited condensed consolidated financial statements should be read in conjunction with Molycorp’s consolidated financial statements and related notes for the year ended December 31, 2011, included in Molycorp's Current Report on Form 8-K filed on August 16, 2012.

The accompanying unaudited condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, and which, in the opinion of management, are necessary for the fair presentation of Molycorp’s financial position, results of operations and cash flows at September 30, 2012, and for all periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

The preparation of the financial statements, in accordance with GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on the Company’s historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ significantly from these estimates under different assumptions and conditions. Significant estimates made by management in the accompanying financial statements include the collectability of accounts receivable, the recoverability of inventory, the useful lives and recoverability of long-lived assets such as property, plant and equipment, intangible assets and investments, capital leases, uncertain tax positions, the fair values of assets acquired and liabilities assumed, including business combinations, and the adequacy of the Company’s asset retirement obligations.

As discussed in Note 15 of Molycorp’s Current Report on Form 8-K filed on August 16, 2012, the Company revised its previously reported results of operations for the third quarter of 2011 to correct an error in the elimination of intercompany sales in that interim period.

In addition, certain prior period amounts have been reclassified to conform to the current period presentation. Such reclassifications did not affect results of operations.

(2) Capital Requirements

Cash expenditures for the Molycorp Mountain Pass facility plant modernization and expansion efforts, including achieving an annual production capacity of 19,050 mt (“Project Phoenix Phase 1”), the second phase capacity expansion plan to 40,000 mt (“Project Phoenix Phase 2”) and other remaining 2012 capital projects related to operations at the Molycorp Mountain Pass facility are expected to total approximately $170.0 million for the fourth quarter of 2012, and approximately $305.0 million in the first half of 2013, respectively.

7

These estimated cash expenditures described above represent the estimated remaining expenditures for Project Phoenix Phase 1, Project Phoenix Phase 2 and the Company's other remaining 2012 capital projects related to operations at the Molycorp Mountain Pass facility. Including the applicable remaining expenditures, the aggregate cost of Project Phoenix Phase 1 and Project Phoenix Phase 2 is estimated to be approximately $1.25 billion for engineering, procurement and construction (“EPC”), preliminary engineering, insurance, permitting, legal, start-up, commissioning and other costs. All amounts for future capital spending are estimates that include certain discretionary amounts and are subject to change as the projects are further developed. These estimates do not include capitalized interest.

The estimated total costs for Project Phoenix Phase 1 and Project Phoenix Phase 2 include estimated additional EPC expenditures totaling up to $150.0 million for corrections resulting from certain defective engineering work, other engineering, design and scope changes and other cost increases. The Company is pursuing actions to recoup certain costs arising from defective engineering work, including making claims against applicable insurance policies, although there can be no assurance that the Company will be able to recoup all or any portion of such costs. The Company regularly monitors its capital projects to identify opportunities to reduce their total costs.

Anticipated capital expenditures at all other operating facilities of the Company are expected to be approximately $10.0 million during the fourth quarter of 2012. See Note 7.

Other cash requirements include planned contributions to Intermetallics Japan (“IMJ”), the Company's joint venture to manufacture sintered NdFeB permanent rare earth magnets. Molycorp will invest, upon achievement of certain milestones, Japanese Yen (JPY) 2.5 billion in cash, in exchange for ordinary shares of IMJ. The actual remittance amounts will vary depending on the future exchange rate between the U.S. dollar and the Japanese Yen, and the achievement of certain milestones by the joint venture. The Company invested $27.7 million (representing JPY 2.2 billion) to IMJ through September 30, 2012, and plans to invest an additional JPY 300 million (or approximately $3.8 million based on the JPY/ U.S. dollar exchange rate at September 30, 2012) in September 2013. See Note 10. The Company also anticipates making cash investments in other current and new ventures consistent with its mine-to-magnets strategy totaling approximately $8.0 million in the fourth quarter of 2012 and approximately $20.0 million in 2013.

Molycorp expects to fund the remaining capital expenditures under Project Phoenix Phase 1, Project Phoenix Phase 2 and other capital expenditures related to operations at the Molycorp Mountain Pass facility and all other operating facilities, as well as working capital and other cash requirements, with its available cash balances of $436.0 million at September 30, 2012, anticipated future cash flow from operations, and potential proceeds from revolving credit facilities or certain equipment financing that the Company is currently pursuing in its normal process of properly managing its cash and working capital requirements.

There can be no assurance that the Company will be successful in securing access to additional cash proceeds through the revolving credit facilities and lease or loan financing for certain equipment that it is currently pursuing, or other forms of financing on commercially acceptable terms, or at all. Accordingly, if necessary, the Company believes it has the ability to curtail capital expenditures and revise its current business plan to the extent necessary to preserve adequate liquidity sufficient to sustain operations.

(3) Segment Information

In the third quarter of 2012, management reorganized the Company's operations into four new reportable segments to better reflect its primary activities as a global rare earth and magnetics enterprise: Resources; Chemicals and Oxides; Magnetic Materials and Alloys; and Rare Metals. The new composition of the Company's reportable segments is based on a combination of product lines and technologies aligned with its mine-to-magnet strategy.

The Resources segment includes: the Company's operations at its Molycorp Mountain Pass facility where it conducts rare earth minerals extraction to produce rare earth concentrates; REO, including lanthanum, cerium, didymium, neodymium, praseodymium and yttrium; heavy rare earth elements, such as samarium, europium, gadolinium, terbium, dysprosium, and others; didymium rare earth metal; and SorbX^TM (formerly XSORBX), a line of proprietary rare earth-based water treatment products.

The Chemicals and Oxides segment includes: production of REO at the Company's operations in Sillamäe, Estonia; heavy rare earths from the Company's facilities in Jiangyin, Jiangsu Province, China; and production of REO, salts of rare earth elements ("REEs"), zirconium-based engineered materials and mixed rare earth/zirconium oxides from the Company's facilities

8

in Zibo, Shandong Province, China. Rare earths products and zirconium-based engineered products are primarily supplied to the automotive catalyst, electronics, ceramic, clean technology and glass industries.

The Magnetic Materials and Alloys segment includes: the production of Neo Powders through Molycorp's wholly-owned manufacturing facilities in Tianjin, China and Korat, Thailand, under the Molycorp Magnequench brand. Neo Powders are used to make bonded magnets for a variety of electronic and mechanical products such as micro motors, precision motors, sensors and other applications requiring high levels of magnetic strength, flexibility, small size and reduced weight. This operating segment also includes manufacturing of neodymium and samarium magnet alloys, other specialty alloy products and rare earth metals at the Company's facility in Tolleson, Arizona.

The Rare Metals segment comprises: Molycorp's production of gallium, indium, tantalum and rhenium from its operations in Quapaw, Oklahoma; Blanding, Utah; Peterborough, Ontario; Napanee, Ontario; Sagard, Germany; and Hyeongok Industrial Zone in South Korea. This operating segment also includes tantalum and niobium from the Company's operations in Sillamäe, Estonia. Rare metals are primarily used in the wireless, light-emitting diode, flat panel display, turbine, solar and catalyst industries.

The asset retirement obligation is recognized only within the Resources segment, and certain government grants are applicable only to the Estonian operations within the Chemicals and Oxides and Rare Metals segment. In addition, the annual profit earned from the Estonian operations are not taxed. In accordance with the Estonian Income Tax Act, only distribution of annual profit is subject to income tax in Estonia. Intersegment sales and transfers are based on similar arms-length transactions with third parties at the time of the sale.

    As noted below, some of the information for the nine months ended September 30, 2012 is actually for the period from June 12, 2012 (following the acquisition of Molycorp Canada) through September 30, 2012.

9

Three months ended September 30, 2012 (In thousands)	Resources			Chemicals and Oxides			Magnetic Materials and Alloys			Rare Metals			Eliminations(a)			Corporate and other(b)			Total Molycorp, Inc.
Sales:
External	$	17,150		$	87,820		$	74,789		$	25,845		$	—					$	205,604
Intersegment	3,745			11,559			—			—			(15,304		)				—
Total sales	$	20,895		$	99,379		$	74,789		$	25,845		$	(15,304	)				$	205,604
Depreciation, amortization and accretion	$	(4,035	)	$	(5,685	)	$	(8,857	)	$	(1,715	)	$	—		$	(43	)	$	(20,335	)
Operating (loss) income	$	(23,966	)	$	2,149		$	1,419		$	(3,774	)	$	369		$	(16,526	)	$	(40,329	)
(Loss) income before income taxes and equity earnings	$	(25,506	)	$	1,201		$	1,215		$	(3,812	)	$	369		$	(17,212	)	$	(43,745	)
Total assets at September 30, 2012 (d)	$	1,686,524		$	565,673		$	536,299		$	79,996		$	(161,201	)	$	178,465		$	2,885,756
Capital expenditures (c)	$	187,611		$	2,597		$	1,432		$	2,837		$	—		$	1,387		$	195,864

Nine months ended September 30, 2012 (In thousands)	Resources			Chemicals and Oxides			Magnetic Materials and Alloys			Rare Metals			Eliminations(a)			Corporate and other(b)			Total Molycorp, Inc.
Sales:
External	$	78,162		$	134,158		$	125,277		$	57,054		$	—					$	394,651
Intersegment	5,977			15,496			—			—			(21,473		)				—
Total sales	$	84,139		$	149,654		$	125,277		$	57,054		$	(21,473	)				$	394,651
Depreciation, amortization and accretion	$	(8,743	)	$	(7,419	)	$	(10,810	)	$	(4,358	)	$	—		$	(96	)	$	(31,426	)
Operating (loss) income	$	(23,594	)	$	(21,863	)	$	(1,544	)	$	(1,947	)	$	24,480		$	(66,804	)	$	(91,272	)
(Loss) income before income taxes and equity earnings	$	(25,044	)	$	(23,663	)	$	(2,381	)	$	(2,998	)	$	24,480		$	(113,546	)	$	(143,152	)
Capital expenditures (c)	$	675,836		$	6,615		$	1,612		$	6,955		$	—		$	1,733		$	692,751

________________________

(a) The net elimination in operating results includes cost of sales elimination of $15,673 for three months ended September 30, 2012, and $45,952 for the nine months ended September 30, 2012. The cost of sales elimination consists of the intercompany gross profits as well as elimination of lower of cost or market adjustments related to intercompany inventory. The $161,201 of total assets elimination is comprised of $159,009 of intercompany investments and $2,192 of intercompany accounts receivable and profits in inventory.

(b) Corporate loss before income taxes and equity earnings includes business development costs, personnel and related costs, including stock-based compensation expense, accounting and legal fees, occupancy expense, information technology costs and interest expense. Other consists of nominal expenses incurred by the sales office in Tokyo, Japan. Total corporate assets is comprised primarily of cash and cash equivalents.

(c) On an accrual basis excluding capitalized interest.

(d) Excludes goodwill of $501.6 million arising on the Molycorp Canada acquisition which has not been allocated to its operating segments.

In prior periods, the basis of segmentation of the Company's activities was the location of its operations. As a result of the changes in the composition of the Company's reportable segments discussed above, the prior period operating segments presentation has been revised for comparative purposes. Some of the information under Chemicals and Oxides and Rare Metals for the nine months ended September 30, 2011 is actually for the period from April 1, 2011 (the beginning of the reporting period of Molycorp Silmet) through September 30, 2011. Some of the information under Magnetic Materials and Alloys for the nine months ended September 30, 2011 is actually for the period from April 15, 2011(the beginning of the reporting period of MMA) through September 30, 2011.

10

Three months ended September 30, 2011 (In thousands)	Resources			Chemicals and Oxides			Magnetic Materials and Alloys		Rare Metals			Eliminations(e)			Corporate and other(b)			Total Molycorp, Inc.
Sales:
External	$	94,342		$	15,927		$	14,449	$	13,332		$	—					$	138,050
Intersegment	30,535			6,652			—		—			(37,187		)				—
Total sales	$	124,877		$	22,579		$	14,449	$	13,332		$	(37,187	)				$	138,050
Depreciation, amortization and accretion	$	(2,715	)	$	(1,627	)	$	128	$	(1,386	)	$	—		$	—		$	(5,600	)
Operating income (loss)	$	101,727		$	2,682		$	610	$	(3,148	)	$	(22,329	)	$	(12,597	)	$	66,945
Income (loss) before income taxes	$	101,606		$	1,559		$	614	$	(4,121	)	$	(22,329	)	$	(13,172	)	$	64,157
Total assets at September 30, 2011	$	632,098		$	52,955		$	33,032	$	69,361		$	(154,710	)	$	552,706		$	1,185,442
Capital expenditures (c)	$	106,162		$	2,300		$	—	$	—		$	—		$	—		$	108,462

(e) The total assets elimination of $154,710 is comprised of $102,357 of intercompany investments and $52,353 of intercompany accounts receivable and profits in inventory.

Nine months ended September 30, 2011 (In thousands)	Resources			Chemicals and Oxides			Magnetic Materials and Alloys			Rare Metals			Eliminations			Corporate and other(b)			Total Molycorp, Inc.
Sales:
External	$	180,951		$	31,419		$	24,699		$	26,858		$	—					$	263,927
Intersegment	46,482			10,290			—			—			(56,772		)				—
Total sales	$	227,433		$	41,709		$	24,699		$	26,858		$	(56,772	)				$	263,927
Depreciation, amortization and accretion	$	(7,538	)	$	(1,707	)	$	(271	)	$	(1,456	)	$	—		$	—		$	(10,972	)
Operating income (loss)	$	163,392		$	10,333		$	(586	)	$	(175	)	$	(31,514	)	$	(34,684	)	$	106,766
Income (loss) before income taxes	$	163,234		$	9,232		$	(580	)	$	(1,124	)	$	(31,514	)	$	(34,945	)	$	104,303
Capital expenditures (c)	$	218,128		$	4,672		$	—		$	—		$	—		$	—		$	222,800

11

(4) Trade Accounts Receivable

Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company reviews the need for an allowance for doubtful accounts on a quarterly basis. At September 30, 2012 and December 31, 2011, the allowance for doubtful accounts was $2.6 million and $0, respectively.

(5) Inventory

At September 30, 2012 and December 31, 2011, inventory consisted of the following (in thousands):

	September 30, 2012		December 31, 2011
Current:
Concentrate stockpiles	$	5,666	$	3,704
Raw materials	93,909		44,770
Work in process	60,754		16,602
Finished goods	114,671		45,045
Materials and supplies	6,133		1,822
Total current	$	281,133	$	111,943
Long-term:
Concentrate stockpiles	$	1,322	$	1,144
Raw materials	8,279		3,186
Finished goods	—		32
Total long-term	$	9,601	$	4,362

Assessment of normal production levels

For the three months ended September 30, 2012 and 2011, Molycorp determined that $3.9 million and $0.8 million, respectively, of production costs would have been allocated to additional production, assuming Molycorp had been operating at normal production ranges. For the nine months ended September 30, 2012 and 2011, the Company determined that $9.8 million and $4.3 million, respectively, of production costs would have been allocated to additional production, assuming the Company had been operating at normal production ranges. As a result, these costs were excluded from inventory and instead expensed during the applicable periods. The assessment of normal production levels is judgmental and is unique to each quarter.

Write-downs of inventory

As a result of production or purchase costs in excess of net realizable value, the Company recognized write-downs of inventory of $15.0 million and $0 for the three months ended September 30, 2012 and 2011, respectively, and $41.1 million and $0.6 million for the nine months ended September 30, 2012 and 2011, respectively. In addition, the Company recognized write-downs of work-in-process and stockpile inventory totaling $0 and $0.1 million for the three months ended September 30, 2012 and 2011, respectively, and $0 and $2.3 million for the nine months ended September 30, 2012 and 2011, respectively, based on adjustments to estimated REO quantities.

(6) Deposits

The Company had $23.3 million in deposits reported as non-current assets at September 30, 2012 and December 31, 2011, respectively. The deposits at September 30, 2012 consist of $20.6 million under an escrow arrangement for the Company’s facilities agreement with Kern River Gas Transmission Company ("Kern River"), $1.5 million related to the Company’s construction insurance program and $1.2 million comprised primarily of other deposit requirements.

(7) Property, Plant and Equipment, net

The Company capitalized $218.1 million and $108.5 million in plant modernization and other capital costs for the three months ended September 30, 2012 and 2011, respectively, and $728.2 million and $222.8 million for the nine months

12

ended September 30, 2012 and 2011, respectively. These amounts include capitalized interest of $22.2 million and $3.1 million for the three months ended September 30, 2012 and 2011, respectively, and $35.5 million and $3.8 million for the nine months ended September 30, 2012 and 2011, respectively.

Capital expenditures under Project Phoenix Phase 1 and Project Phoenix Phase 2, and other capital projects related to operations at the Molycorp Mountain Pass facility, totaled $185.5 million and $102.2 million for the three months ended September 30, 2012 and 2011, respectively, and $664.1 million and $208.2 million for the nine months ended September 30, 2012 and 2011, respectively. These amounts are on an accrual basis and exclude capitalized interest.

At September 30, 2012 and December 31, 2011, property, plant and equipment consisted of the following (in thousands):

	September 30, 2012			December 31, 2011
Land	$	12,292		$	11,059
Land improvements	63,268			15,748
Buildings and improvements	112,182			23,677
Plant and equipment	157,970			68,441
Vehicles	2,526			1,235
Computer software	5,067			3,002
Furniture and fixtures	733			464
Construction in progress (a)	1,006,632			436,547
Capital Leases	15,658			—
Mineral properties	24,399			24,692
Property, plant and equipment at cost	1,400,727			584,865
Less accumulated depreciation	(37,283		)	(23,237		)
Property, plant and equipment, net	$	1,363,444		$	561,628

(a) Represents costs incurred for Project Phoenix Phase 1 and Project Phoenix Phase 2 and all other capital projects. See Note 2.

(8) Mineral Properties and Development Costs

Mineral properties and development costs, which are referred to collectively as mineral properties, include acquisition costs, drilling costs, and the cost of other development work, all of which are capitalized. The Company began depleting mineral properties in 2012 using the units of production method over estimated proven and probable reserves. For the three and nine months ended September 30, 2012, the Company capitalized a nominal amount of depletion costs in work-in-process inventory related to the reserves that were mined and crushed during these periods.

(9) Intangible Assets

At September 30, 2012 and December 31, 2011, amortizable intangible assets consisted of the following (in thousands):

13

	September 30, 2012			December 31, 2011
Customer relationships	$	350,925		$	2,153
Rare earth quotas	80,300			—
Patents	39,753			—
Trade name	16,586			786
Land use rights	3,420			—
Other	4,419			516
Gross carrying amount	495,403			3,455
Less accumulated amortization	(16,230		)	(383		)
Net carrying amount	$	479,173		$	3,072

At September 30, 2012, the net carrying amounts of customer relationships, rare earth quotas, patents, trade name, and other intangible assets included preliminary estimates of $476.4 million as a result of the Molycorp Canada acquisition. The Company expects to complete the final determination of these estimates and related estimated lives for amortizable intangible assets no later than the second quarter of 2013.

(10) Investments

Boulder Wind Power, Inc.

On September 13, 2011, the Company invested $20.0 million into Boulder Wind Power, Inc. Series B convertible preferred stock, which is accounted for at cost. At September 30, 2012, the fair value of this investment was not estimated as there were no identified events or changes in circumstances that may have had a significant adverse effect on the fair value of the investment.

Intermetallics Japan Joint Venture

On November 28, 2011, Molycorp, Daido Steel Co., Ltd. (“Daido”) and Mitsubishi Corporation (“Mitsubishi”) entered into a preliminary shareholders agreement for the purpose of establishing a new private company, IMJ, to manufacture sintered NdFeB permanent rare earth magnets. The capital contribution ratio of the newly formed company is 30.0% by Molycorp, 35.5% by Daido and 34.5% by Mitsubishi. According to the definitive shareholders agreement, which was signed in January 2012, Molycorp will contribute, upon achievement of certain milestones and subject to the approval of Molycorp’s Board of Directors, Japanese Yen (JPY) 2.5 billion in cash in exchange for ordinary shares of IMJ over a period of twelve months. The actual remittance amounts will vary depending on the future exchange rate between the U.S. dollar and the Japanese Yen, and the achievement of certain milestones by the joint venture. The Company contributed $27.7 million (representing JPY 2.2 billion) to IMJ through September 30, 2012.

Molycorp accounts for this investment under the equity method because it has the ability to exercise significant influence over the operating and financial policies of IMJ, as evidenced by Molycorp’s ownership share and its proportional voting rights and representation in the Board of Directors of IMJ. The condensed consolidated statement of operations and comprehensive income for the three and nine months ended September 30, 2012 include a loss of $0.2 million and $0.8 million, respectively, associated with this equity method interest.

Ganzhou Keli Rare Earth New Material Co., Ltd.

As a result of the Molycorp Canada acquisition in June 2012, Molycorp acquired a 25% ownership interest in Ganzhou Keli Rare Earth New Material Co., Ltd. (“Keli”), a company that converts REO into metals for use in Neo Powders. The preliminary purchase allocation attributable to this investment at the time of the Molycorp Canada acquisition was $12.2 million. Molycorp accounts for this ownership interest under the equity method because it has the ability to exercise significant influence over the operating and financial policies of Keli, as evidenced by Molycorp’s ownership share and its proportional voting rights. The condensed consolidated statements of operations and comprehensive income include a gain of $0.3 million for the period from June 12, 2012 to September 30, 2012 associated with this equity method ownership interest.

14

Toda Magnequench Magnetic Materials Co. Ltd.

As a result of the Molycorp Canada acquisition in June 2012, Molycorp acquired a 33% ownership interest in Toda Magnequench Magnetic Materials Co. Ltd. (“TMT”), a company that produces rare earth magnetic compounds with Neo Powders supplied by Magnequench (Tianjin) Company Limited in its normal course of business. The preliminary purchase allocation attributable to this investment at the time of the Molycorp Canada acquisition was $1.6 million. Molycorp accounts for this ownership interest under the equity method because it has the ability to exercise significant influence over the operating and financial policies of TMT, as evidenced by Molycorp’s ownership share and its proportional voting rights.

Ingal Stade GmbH

As a result of the Molycorp Canada acquisition in June 2012, Molycorp acquired a 50% ownership interest in Ingal Stade GmbH (“Ingal Stade”), a joint venture facility in Stade, Germany, which extracts gallium metal from alumina smelter bayer liquor with purity level of 5N (99.999%) or higher. The preliminary purchase allocation attributable to this investment at the time of the Molycorp Canada acquisition was $4.9 million. Molycorp accounts for this ownership interest under the equity method.

Atlantic Metals & Alloys, LLC

As a result of the Molycorp Canada acquisition in June 2012, Molycorp acquired a 19.5% ownership interest in Atlantic Metals & Alloys,LLC, a company which provides refining services for residues and scrap of the rare and platinum group metals. The preliminary purchase allocation attributable to this investment at the time of the Molycorp Canada acquisition was $1.4 million. Molycorp accounts for this ownership interest under the cost method. At September 30, 2012, the fair value of this investment was not estimated as there were no identified events or changes in circumstances that may have had a significant adverse effect on the fair value of the investment.

Vive Crop Protection

As a result of the Molycorp Canada acquisition in June 2012, Molycorp acquired a 7% ownership interest in Vive Crop Protection, a company that specializes in the formulation of active ingredients used in crop protection. The preliminary purchase allocation attributable to this investment at the time of the Molycorp Canada acquisition was $0.9 million. Molycorp accounts for this ownership interest under the cost method. At September 30, 2012, the fair value of this investment was not estimated as there were no identified events or changes in circumstances that may have had a significant adverse effect on the fair value of the investment.

(11) Acquisitions

On June 11, 2012, Molycorp completed the acquisition of all of the outstanding equity of Molycorp Canada's predecessor company pursuant to the terms of an arrangement agreement (the "Arrangement Agreement") for an aggregate purchase price of approximately $1,192.3 million. Pursuant to the Arrangement Agreement, Molycorp Canada's former shareholders elected to receive: (a) cash consideration equal to Canadian dollars ("Cdn") $11.30 per share of Molycorp Canada's predecessor company's common stock; or (b) share consideration of 0.4242 shares of Molycorp common stock or 0.4242 shares (the "Exchangeable Shares") issued by MCP Exchangeco Inc., Molycorp's wholly-owned Canadian subsidiary, which are exchangeable for shares of Molycorp's common stock on a one for one basis, per each share of Molycorp Canada's predecessor company's common stock; or (c) a combination of cash and shares of Molycorp common stock or Exchangeable Shares, all subject to the proration mechanics set forth in the Arrangement Agreement.

The consideration paid to Molycorp Canada's former shareholders was comprised of approximately $908.2 million in cash, exclusive of realized losses on the contingent forward contract to purchase $870.0 million Canadian dollars, accounted for as a separate transaction apart from the business combination, as further discussed in Note 25. Additionally, 13,545,426 shares of Molycorp common stock and 507,203 Exchangeable Shares were issued and collectively valued at $284.1 million based on the closing price of the Company's common stock on the acquisition date in accordance with the relevant accounting guidance. The Exchangeable Shares have no par value.

15

The following is a preliminary allocation of the Molycorp Canada purchase price (in thousands) and is based on management's preliminary estimates of the fair value of the tangible and intangible assets and liabilities of Molycorp Canada. This valuation is subject to change as the Company obtains additional information on the assets acquired and liabilities assumed during the acquisition measurement period (up to one year from the acquisition date).

	June 11, 2012
Purchase consideration:
Cash consideration	$	908,181
Fair value of Molycorp common stock and Exchangeable Shares issued	284,144
Total purchase consideration	$	1,192,325
Estimated fair values of the assets and liabilities acquired:
Cash and cash equivalents	$	317,169
Accounts receivable	101,470
Inventory	250,989
Prepaid expenses and other current assets	26,893
Property, plant and equipment	70,391
Investments	21,019
Intangibles	491,786
Goodwill	501,571
Other non-current assets	22,859
Accounts payable and accrued expenses	(138,576		)
Debt - current	(255,056		)
Other current liabilities	(29,939		)
Deferred tax liabilities	(158,177		)
Long-term debt	(281		)
Other non-current liabilities	(14,032		)
Non-controlling interests	(15,761		)
Total purchase consideration	$	1,192,325

The fair value of the accounts receivable acquired includes trade receivables of $101.5 million, which are considered to be fully collectible at September 30, 2012.

Molycorp Canada's intangible assets subject to amortization relate to: a) customer relationships of $348.1 million with a weighted average useful life of approximately fifteen years; b) rare earth quotas of $80.3 million with a useful life of approximately 11 years; c) patents of $39.8 million with a weighted average useful life of approximately two years; d) trade name of $15.8 million with a useful life of approximately ten years; and e) other of $7.8 million with a weighted average useful life of approximately twelve years.

Goodwill associated with the Molycorp Canada acquisition arose primarily because of Molycorp Canada's proven leadership in the development, processing, and distribution of technically advanced rare earth products; greater exposure to the world’s largest and fastest-growing rare earths consuming market; deferred tax liabilities and expected synergies that do not qualify for separate recognition. The goodwill is not amortized and is not deductible for tax purposes. As the purchase price allocation is not complete, the Company has not assigned the goodwill to its various reporting units.

The amounts of Molycorp Canada's sales, earnings and earnings per share included in the Company’s condensed consolidated statements of operations since the acquisition date, and the sales, earnings and earnings per share of the combined entity had the acquisition date been January 1, 2011, are as follows:

16

(In thousands, except per share amounts)	Sales		Net Income (Loss)			Net Income (Loss) Attributable To Molycorp			EPS Basic
Actual July 1, 2012 to September 30, 2012 (acquiree)	$	162,764	$	1,118		$	(2,322	)	$	(0.02	)
Actual June 11, 2012 to September 30, 2012 (acquiree)	$	206,397	$	1,165		$	(2,955	)	$	(0.03	)
Unaudited pro forma January 1, 2012 to September 30, 2012 (combined entity)	$	729,469	$	(74,229	)	$	(82,056	)	$	(0.77	)
Unaudited pro forma July 1, 2011 to September 30, 2011 (combined entity)	$	385,889	$	108,386		$	105,947		$	0.94
Unaudited pro forma January 1, 2011 to September 30, 2011 (combined entity)	$	860,707	$	200,951		$	192,300		$	1.69

The unaudited pro forma amounts are not necessarily indicative of the operating results that would have occurred if the Molycorp Canada acquisition had taken place on January 1, 2011.

The unaudited pro forma sales, earnings and earnings per share of the combined entity above are adjusted: a) to eliminate the effect of sales and costs that occurred previous to the business combination between the Company and Molycorp Canada; b) to reflect the net incremental depreciation and amortization expense as a result of the allocation of the purchase price to certain depreciable and amortizable assets with useful lives ranging from two to 30 years; c) the tax effect of unaudited pro forma adjustments using the Molycorp federal, state and international statutory tax rates based on the applicable tax jurisdictions; and d) the estimated net increase of interest expense associated with the issuance of the Company's 10% Senior Secured Notes (as defined below) as part of the acquisition. The unaudited pro forma earnings of the combined entity for the nine months ended September 30, 2012 were also adjusted to exclude $115.2 million of non-recurring direct transaction costs. The weighted average number of shares outstanding utilized in the EPS basic calculation have been adjusted to reflect the additional shares issued pursuant to the acquisition of Molycorp Canada and the related Molibdenos y Metales S.A. equity financing further discussed in Note 16.

For the three and nine months ended September 30, 2012, the Company recognized approximately $0.5 million and $62.0 million, respectively, of transaction costs related to the Molycorp Canada acquisition in the condensed consolidated statements of operations and comprehensive income as follows:    

(In thousands)	Three Months Ended September 30, 2012		Nine Months Ended September 30, 2012
Corporate development
Legal, accounting and advisory fees	$	465	$	16,498
Other expenses:
Contingent forward contract loss	$	—	$	37,589
Interest expense:
Bridge loan fee	$	—	$	7,937

Molycorp Silmet and MMA

The following table summarizes the purchase prices and opening balance sheets for the acquisition of 90.023% controlling interest in Molycorp Silmet on April 1, 2011 and of MMA on April 15, 2011 (in thousands):

17

Effective acquisition date for financial reporting purposes:	Molycorp Silmet April 1, 2011			MMA April 15, 2011
Purchase consideration:
Cash consideration	$	9,021		$	17,500
Fair value of Molycorp common stock issued	72,653			—
Total purchase consideration	$	81,674		$	17,500
Fair values of the assets and liabilities acquired:
Cash	$	105		$	6,395
Accounts receivable and other current assets	8,626			5,474
Inventory	37,404			11,327
Property, plant and equipment, net	63,393			4,512
Intangible assets subject to amortization	2,669			—
Goodwill	1,455			1,977
Liabilities	(19,974		)	(8,989		)
Deferred tax liabilities	—			(3,196		)
Long-term debt	(3,184		)	—
Noncontrolling interest	(8,820		)	—
Total purchase consideration	$	81,674		$	17,500

The fair value of the accounts receivable acquired includes trade receivables of $5.0 million for Molycorp Silmet and $4.9 million for MMA. These trade receivables were collected by December 31, 2011. Molycorp Silmet’s intangible assets subject to amortization relate primarily to customer relationships with a weighted average useful life of 15 years. Goodwill associated with the Molycorp Silmet acquisition arose primarily because of the acquired workforce. Goodwill associated with the MMA acquisition arose primarily because of the requirement to record a deferred tax liability for the difference between the assigned values and the tax basis of assets acquired and liabilities assumed at amounts that do not reflect fair value. The goodwill is not amortized and is not deductible for tax purposes. The fair value of the noncontrolling interest in Molycorp Silmet as of April 1, 2011 was valued using a combination of the market approach and income approach.

The pro forma sales, earnings and earnings per share of the Company had both acquisitions occurred on January 1, 2011, are as follows:

(In thousands, except per share amounts)	Sales		Net Income		Net Income Attributable To Molycorp		EPS Basic
Unaudited pro forma January 1, 2011 to September 30, 2011 (combined entity)	$	297,400	$	104,170	$	103,457	$	1.17

The unaudited pro forma amounts are not necessarily indicative of the operating results that would have occurred if these acquisitions had taken place on January 1, 2011.

The 2011 earnings of the combined entity were adjusted to exclude $19.6 million of intercompany sales and $1.8 million of non-recurring acquisition-related costs the Company incurred to acquire Molycorp Silmet and MMA, and to reverse $1.1 million of purchase price variance MMA capitalized during the first quarter of 2011.

Molycorp Silmet

On April 1, 2011, Molycorp acquired 80% of the outstanding shares of Molycorp Silmet from AS Silmet Grupp in exchange for 1,593,419 shares of Molycorp common stock contractually valued at $80.0 million based on the average closing price of the Company’s common stock as reported by The New York Stock Exchange for the 20 consecutive trading days immediately preceding April 1, 2011, the acquisition date.

Generally, the acquisition-date fair value of shares of common stock transferred by the acquirer is the closing price of that stock on the same date adjusted by a discount that a market participant would require as a result of any restrictions on the sale or transferability of the stock. The fair value of common stock of $72.7 million disclosed in the table above is based on the

18

closing price of the Company’s common stock on the acquisition date, net of an estimated discount of 23% that a market participant would require given that issuance of the shares of common stock Molycorp transferred in consideration to AS Silmet Grupp was not registered under the Securities Act of 1933 (the "Securities Act") and such shares were subject to certain lock-up provisions, which limited AS Silmet Grupp’s ability to sell these shares. AS Silmet Grupp retained a 9.977% ownership interest in Molycorp Silmet on the acquisition date; Molycorp acquired the other 10.023% from Treibacher Industrie AG for $9.0 million in cash also on April 1, 2011.

On October 24, 2011, the Company acquired the remaining 9.977% ownership interest in Molycorp Silmet for $10.0 million in cash, which resulted in an adjustment to Additional Paid-In Capital of $0.4 million for the difference between the consideration paid and the carrying value of the noncontrolling interest at October 24, 2011.

The Molycorp Silmet acquisition provided Molycorp with a European base of operations and increased the Company’s yearly REO production capacity by approximately 3,000 mt. Molycorp Silmet sources a portion of rare earth feed stocks for production of its products primarily from the Molycorp Mountain Pass facility. The main focus of Molycorp Silmet is on the production of REO and metals, including didymium metal, a critical component in the manufacture of NdFeB permanent rare earth magnets. Molycorp Silmet’s manufacturing operation is located in Sillamäe, Estonia.

MMA

On April 15, 2011, Molycorp completed the acquisition from Santoku Corporation (“Santoku”) of all the issued and outstanding shares of capital stock of Santoku America, Inc., which is now known as MMA, an Arizona-based corporation, in an all-cash transaction for $17.5 million. The acquisition provided Molycorp with access to certain intellectual properties relative to the development, processing and manufacturing of neodymium and samarium magnet alloy products. As part of the stock purchase agreement, Santoku will provide consulting services to Molycorp for the purpose of maintaining and enhancing the quality of MMA’s products. Molycorp and Santoku also entered into five-year marketing and distribution agreements for the sale and distribution of neodymium and samarium magnet alloy products produced by each party. Additionally, the parties entered into a rare earth products purchase and supply agreement through which MMA will supply Santoku with certain rare earth alloys for a two-year period at prices equal to the feedstock cost plus the applicable product premium as such terms are defined in the agreement.

(12) Accrued Expenses

Accrued expenses at September 30, 2012 and December 31, 2011 consisted of the following (in thousands):

	September 30, 2012		December 31, 2011
Defined contribution plan	$	1,928	$	1,088
Professional fees	4,456		—
Accrued payroll and related benefits	8,246		3,024
Sales and use tax	9,412		1,367
Bonus accrual	3,683		4,845
Interest payable	27,733		345
Advance from customer	2,898		—
Other accrued expenses	7,933		2,229
Total accrued expenses	$	66,289	$	12,898

(13) Asset Retirement Obligation

The following table presents the activity in the Company’s asset retirement obligation for the nine months ended September 30, 2012, and for the year ended December 31, 2011 (in thousands):

19

	Nine Months Ended September 30, 2012			Year Ended December 31, 2011
Balance at beginning of period	$	15,541		$	12,471
Obligations settled	(1,487		)	(1,030		)
Accretion expense	897			955
Revisions in estimated cash flows	7,872			2,508
Gain on settlement	—			637
Balance at end of period	$	22,823		$	15,541

The balances above for the nine months ended September 30, 2012 and the year ended December 31, 2011, include a short-term portion of $2.1 million and $0.4 million, respectively, which were recorded under other current liabilities. The Company is required to provide the applicable governmental agencies with financial assurances relating to its closure and reclamation obligations. At September 30, 2012, the Company had financial assurance requirements of $28.8 million, which were satisfied with surety bonds placed with California state and regional agencies.

(14) Debt and Capital Lease Obligations

On August 22, 2012, the Company issued of $360.0 million aggregate principal amount of its 6.00% Convertible Senior Notes due 2017 (the “6.00% Convertible Notes”). On August 28, 2012, the underwriters of the 6.00% Convertible Notes exercised their option to purchase an additional $54.0 million aggregate principal amount of the 6.00% Convertible Notes. Total net proceeds from the issuance of the 6.00% Convertible Notes were $395.7 million, after deducting the underwriting discounts and commissions. Certain of the Company's directors, officers and other related parties purchased $6.4 million of the aggregate principal amount of the 6.00% Convertible Notes, for which the Company did not pay any underwriting discounts and commissions.

The 6.00% Convertible Notes are Molycorp's senior unsecured obligations with interest payable semi-annually in arrears on March 1 and September 1 of each year, commencing on March 1, 2013. The 6.00% Convertible Notes will mature on September 1, 2017, unless earlier repurchased, redeemed or converted in accordance with their terms, and will be convertible at any time prior to the second scheduled trading day immediately preceding the maturity date into shares of common stock, cash, or a combination thereof, at Molycorp's election. The conversion rate will initially be 83.333 shares of common stock per $1,000 principal amount of 6.00% Convertible Notes (equivalent to an initial conversion price of approximately $12 per share of common stock), subject to customary adjustments. Molycorp will have the right to redeem the 6.00% Convertible Notes on or after September 1, 2015 if the last reported sale price of its common stock has been at least 130% of the conversion price then in effect for at least 20 trading days during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which Molycorp provides notice of redemption at a redemption price equal to 100% of the principal amount of the 6.00% Convertible Notes to be redeemed, plus accrued and unpaid interest. The 6.00% Convertible Notes rank equal in right of payment to existing and future liabilities that are not expressly subordinated to the 6.00% Convertible Notes, and rank effectively junior to Molycorp's existing and future secured indebtedness.

The Company separately accounts for the liability and equity components of convertible debt instruments, such as the 6.00% Convertible Notes, that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer's economic interest cost. The additional discount on the liability component is amortized to interest cost over the term of the 6.00% Convertible Notes. The effective interest rate on the liability component is 4.6%. The equity component of the 6.00% Convertible Notes is included in the additional paid-in capital section of stockholders' equity on the condensed consolidated balance sheet as of September 30, 2012, and the value of the equity component is treated as original issue discount for purposes of accounting for the debt component of the 6.00% Convertible Notes. As of September 30, 2012, Molycorp recognized a liability component related to the 6.00% Convertible Notes of $328.5 million, which includes a cumulative accretion of $1.5 million related to both the underwriting discounts and the additional discount on the liability component, and an equity component of $68.7 million. The amount of interest costs recognized for the three months ended September 30, 2012 relating to both the contractual interest coupon and amortization of the discount on the liability component was $3.8 million, which was substantially capitalized. Transaction costs related to the issuance of the 6.00% Convertible Notes have been allocated to the liability and equity components in proportion to the allocation of proceeds to the components, and accounted for as debt issuance costs (recognized as interest expense over the life of the 6.00% Convertible Notes using the effective interest method) and equity issuance costs (charged against equity), respectively.

20

Concurrently with, and in order to facilitate the offering of the 6.00% Convertible Notes, the Company entered into a share lending agreement with Morgan Stanley Capital Services LLC (“MSCS”), an affiliate of Morgan Stanley & Co. LLC, under which it agreed to loan to MSCS up to a total of 13,800,000 shares of its common stock (the “Borrowed Shares”)during a period beginning on the date the Company entered into the share lending agreement and ending on or about the maturity date of the 6.00% Convertible Notes, or, if earlier, on or about the date as of which all of the 6.00% Convertible Notes cease to be outstanding as a result of redemption, repurchase, conversion or other acquisition for value. MSCS may terminate all or any portion of the Borrowed Shares at any time, and the Company and MSCS may terminate any or all of the outstanding Borrowed Shares upon a default by the other party under the share lending agreement, including certain breaches by MSCS of its representations and warranties, covenants or agreements under the share lending agreement, or the bankruptcy of Molycorp or MSCS. The Company issued a total of 13,800,000 Borrowed Shares between August 22, 2012 and August 23, 2012 and received no proceeds, but only a nominal lending fee from MSCS for the use of these loaned shares, which represented the fair value assigned to it. For corporate law purposes, the Borrowed Shares are issued and outstanding. However, under the share lending agreement, MSCS has agreed: to pay to Molycorp an amount equal to cash dividends, if any, that Molycorp pays on the Borrowed Shares; to pay or deliver, as the case may be, to the Company any other distribution, other than in a liquidation or a reorganization in bankruptcy, that the Company makes on the Borrowed Shares; and not to vote on the Borrowed Shares on any matter submitted to a vote of Molycorp's stockholders. In view of the contractual undertakings of MSCS in the share lending agreement, which have the effect of substantially eliminating the economic dilution that otherwise would result from the issuance of the Borrowed Shares, the Borrowed Shares will not be considered outstanding for the purpose of computing and reporting Molycorp's earnings per share.

             On May 25, 2012, Molycorp issued $650.0 million aggregate principal amount of senior secured notes due 2020 (the "Senior Notes") in an offering exempt from the registration requirements of the Securities Act. Total net proceeds from the issuance of the Senior Notes were $635.4 million after deducting the initial purchasers' discounts. The Senior Notes bear interest at the rate of 10% per year payable on June 1 and December 1 of each year beginning on December 1, 2012. At any time and from time to time prior to June 1, 2016, the Company may redeem any of the Senior Notes at a price equal to 100% of the principal amount thereof plus an applicable make-whole premium and accrued and unpaid interest. At any time and from time to time from and after June 1, 2016, Molycorp may redeem the Senior Notes, in whole or in part, at a redemption price for the Senior Notes plus accrued and unpaid interest, initially at 105% of the principal amount thereof, but gradually declining to 100% of the principal amount thereof. In addition, at any time and from time to time prior to June 1, 2015, the Company may redeem up to 35% of the aggregate principal amount of the Senior Notes with the net cash proceeds of one or more permitted sales of Molycorp’s capital stock at a redemption price (expressed as a percentage of principal amount) of 110% plus accrued and unpaid interest. Upon the occurrence of a change of control, Molycorp will be required to offer to repurchase all of the Senior Notes. The Senior Notes are senior secured obligations of Molycorp and are guaranteed by certain of Molycorp’s domestic subsidiaries ("Guarantors"). The Senior Notes are secured by first-priority security interest on substantially all of the property and assets of the Company and the Guarantors, subject to a number of exceptions as described in the indenture governing the Senior Notes. A substantial portion of the net proceeds from the offering of the Senior Notes was used to fund the cash consideration the Company paid for Molycorp Canada, with the remainder used for general corporate purposes. The Company, the Guarantors and the initial purchasers of the Senior Notes agreed that the Company and the Guarantor will file an exchange offer registration statement with the SEC within 180 days of the May 25, 2012 issuance date, and use their respective commercially reasonable efforts to have it declared effective at the earliest possible time and in any event within 270 days following the issuance date.

As a result of the Molycorp Canada acquisition, the Company assumed $230.0 million principal amount of subordinated unsecured convertible debentures of the predecessor of Molycorp Canada due December 2017 (the “Debentures”) maturing on December 31, 2017. The Debentures bear interest at 5.00% per annum and are convertible at $13.80 per share of Molycorp Canada's predecessor company. As required under the change of control provisions contained in the original underlying indenture, holders of the Debentures had the option to either require the Company to repurchase the Debentures at par plus accrued interest, convert the Debentures into common shares of Molycorp Canada's predecessor company, including a number of additional “make-whole” shares, or hold the Debentures to maturity. In August 2012, holders of $9.4 million aggregate principal amount of Debentures elected to convert, while holders of $217.9 million aggregate principal amount of Debentures elected to early redeem their Debentures for cash plus accrued interest. Under the term of the indenture governing the Debentures, as amended at the time of the Molycorp Canada acquisition, the holders of the Debenture that converted received, at their election and in lieu of receiving shares of Molycorp Canada's predecessor company, the same cash and/or share consideration that was paid to Molycorp Canada's former shareholders in connection with the acquisition of Molycorp Canada, subject to the same pro-ration calculation, as if such holders had converted immediately prior to the acquisition. As a result of the conversion, a total of $8.0 million, including accrued interest, was paid in cash with the remainder converted into 99,723 shares of Molycorp common stock. Total interest cost related to the Debentures for the period from June 12, 2012 to September 30, 2012 was $0.6 million, inclusive of the interest accrued and paid upon the August 2012 repurchase. As of September 30, 2012, $2.7 million principal amount of the Debentures was outstanding.

21

Additional short-term indebtedness was assumed as part of the acquisition of Molycorp Canada totaling $31.5 million, at September 30, 2012, which relates to various bank loans maturing between July 2012 and December 2012 with a weighted average interest rate of approximately 4.22%.

On September 1, 2010, Molycorp and Kern River entered into a firm Transportation Service Agreement ("TSA") under which Kern River agreed to construct and operate facilities necessary to provide natural gas transportation services to the Mountain Pass facility. Under the terms of the TSA, Molycorp agreed to pay Kern River for the cost attributable to the design, permitting, and construction of the delivery facilities through a transportation service charge of approximately $0.4 million per month for ten years. This charge includes reimbursement to Kern River for construction of the delivery facilities and installation, as well as reimbursement and compensation for transportation services. The term of the TSA commenced on June 1, 2012, the date on which Kern River deemed the TSA facilities ready to provide service. The Company accounted for the TSA as a capital lease under the relevant accounting guidance.

The following tables provide a summary of the current and non-current portions of the debt outstanding at September 30, 2012 and December 31, 2011 (in thousands):

	September 30, 2012
	Current		Non-Current
10% Senior Secured Notes, net of discount, due June 2020	$	—	$	635,802
3.25% Convertible Notes, net of discount, due June 2016	—		196,699
5.00% Debentures, net of discount	—		2,774
6.00% Convertible Notes, net of discount, due June 2017	—		328,494
Bank loans with a weighted average rate of 4.00% due November 2012 - September 2017	32,693		4,435
Total debt	32,693		1,168,204
Capital lease obligations	242		15,324
Total debt and capital lease obligations	$	32,935	$	1,183,528

	December 31, 2011
	Current		Non-Current
3.25% Convertible Notes, net of discount, due June 2016	$	—	$	190,877
Bank loans 2.69% - 3.88% due February 2012 - September 2017	1,516		5,668
Total debt	$	1,516	$	196,545

Scheduled minimum debt repayments are $31.7 million for the remainder of 2012, $1.4 million in 2013, $1.4 million in 2014, $1.3 million in 2015, $230.7 million in 2016, $417.3 million in 2017 and $650.0 million thereafter.

(15) Income Taxes

The Company’s net loss of $85.9 million for the nine months ended September 30, 2012 included $12.2 million in acquisition-related expense, which is a permanent difference between its loss for financial reporting and tax purposes. Molycorp had net deferred income tax liabilities of $162.3 million at September 30, 2012 primarily related to the purchase accounting adjustment associated with the Molycorp Canada acquisition.

At September 30, 2012, Molycorp determined that it, more likely than not, will realize its deferred tax assets and concluded that no valuation allowance is required. In making this determination, management analyzed, among other things, the Company’s recent history of earnings and cash flows, forecasts of future earnings, and the nature and timing of future deductions and benefits represented by the deferred tax assets and liabilities.

The Company has undistributed earnings for several foreign subsidiaries at September 30, 2012, for which deferred taxes have not been provided. Such earnings are considered indefinitely invested in the foreign subsidiaries. If such earnings were repatriated, additional tax expense may result, although the calculation of such additional taxes is not practicable.

22

The net tax effect of the elimination in consolidation of intercompany balances and transactions resulted in a deferred charge and income tax payable of $12.5 million at September 30, 2012.

Each quarter the Company evaluates the liability for uncertain tax positions. As a result of the acquisition of Molycorp Canada on June 11, 2012, some uncertain tax positions have decreased due to a lapse of the applicable statute of limitations, which totaled to $1.4 million, and some due to resolution with tax authorities for $13.7 million. These decreases have been recorded as a discrete income tax benefit in the third quarter of 2012. As a result of the statute of limitations that expire in the next 12 months in various jurisdictions, and possible settlements of audit-related issues with taxing authorities in various jurisdictions, the Company believes that it is reasonably possible that the total amount of its net unrecognized income tax benefits will decrease by approximately $4.0 million to $6.0 million in the next 12 months and, if recognized, would affect the Company's effective income tax rate.

(16) Stockholders’ Equity

At September 30, 2012 and December 31, 2011, the Company had 137,957,451 and 83,896,043 shares of common stock outstanding, respectively, and 2,070,000 shares of 5.50% Series A Mandatory Convertible Preferred Stock (“Convertible Preferred Stock”) outstanding.

Concurrently with the issuance of the 6.00% Convertible Notes discussed in Note 14, the Company issued a total of 13,800,000 shares of its common stock at a price to the public of $10.00 per share (the “Primary Shares”) in a separate underwritten public offering. The underwriters received a 6.00% fee in the form of an underwriter's discount for the Primary Shares plus a $1.5 million flat fee to the representative of the underwriters of the Primary Shares. Certain officers, directors and other related parties of the Company participated in offering of the Primary Shares by purchasing 7,090,000 of the total Primary Shares issued, but no underwriting fees were charged to the Company for the purchase by the insiders.

At the same time of the issuance of the 6.00% Convertible Notes and the Primary Shares, and as further discussed in Note 14, the Company entered into a share lending agreement with MSCS, pursuant to which it has agreed to loan to MSCS 13,800,000 shares of common stock. The Company received no proceeds from the Borrowed Shares, but only a nominal lending fee from MSCS for the use of these loaned shares. The Borrowed Shares are issued and outstanding for corporate law purposes. However, based on certain contractual undertakings of MSCS in the share lending agreement that have the effect of substantially eliminating the economic dilution that otherwise would result from the issuance of the Borrowed Shares, the Borrowed Shares will not be considered outstanding for the purpose of computing and reporting Molycorp's earnings per share.

As a result of the conversion of the Debentures, as further discussed in Note 14, a portion of the Debentures tendered was converted into 99,723 shares of Molycorp common stock.

In connection with of the acquisition of Molycorp Canada on June 11, 2012, Molycorp and MCP Exchangeco Inc. issued an aggregate of 13,545,426 shares of common stock and 507,203 Exchangeable Shares, the latter without par value, in consideration for that portion of the purchase price Molycorp paid to Molycorp Canada’s former shareholders who elected to receive shares of Molycorp common stock in addition to or in lieu of cash on the acquisition date. The $284.1 million fair value recorded in additional paid-in capital related to the issuance of acquisition consideration was based on the closing price of the Company’s common stock on June 11, 2012. As of September 30, 2012, 316,860 shares of the Exchangeable Shares had been converted into shares of Molycorp common stock.

On March 8, 2012, Molibdenos y Metales S.A. (“Molymet”), the world’s largest processor of molybdenum and rhenium, headquartered in Santiago, Chile, purchased 12,500,000 shares of the Company’s common stock for $390.1 million, net of stock issuance costs of $0.1 million, at a purchase price of $31.218 per share, which price was determined based on the average daily volume weighted average price of the Company’s common stock on The New York Stock Exchange for the 20 consecutive trading days immediately preceding the date of the agreement, plus a 10% premium. Pursuant to this investment, Molymet acquired the right to nominate a member of the Company’s Board of Directors for so long as Molymet owns a certain percentage of the Company’s common stock.

In February, May and August 2012, the Company declared a cash dividend of $1.375 per share on the Convertible Preferred Stock, respectively. The Company paid $2.8 million of the aggregate dividend in the third quarter of 2012, and a total of $8.5 million during the nine months ended September 30, 2012.

(17) (Loss) Earnings per Share

23

For the three and nine months ended September 30, 2012 and for the three and nine months ended September 30, 2011, the dividends on the Convertible Preferred Stock were subtracted from net (loss) income attributable to Molycorp stockholders for the purpose of computing the basic and diluted earnings per share.

	Three Months Ended
(In thousands, except share and per share amounts)	September 30, 2012			September 30, 2011
Net (loss) income attributable to Molycorp stockholders	$	(18,891	)	$	45,356
Dividends on Convertible Preferred Stock	(2,846		)	(2,846		)
(Loss) income attributable to common stockholders	(21,737		)	42,510
Weighted average common shares outstanding—basic	117,086,022			83,847,119
Basic (loss) earnings per share	$	(0.19	)	$	0.51
(Loss) income attributable to common stockholders	(21,737		)	42,510
Effect of dilutive 3.25% Convertible Notes	—			404
(Loss) income attributable to common stockholders adjusted for effect of dilution	(21,737		)	42,914
Weighted average common shares outstanding—diluted	117,086,022			87,069,256
Diluted (loss) earnings per share	$	(0.19	)	$	0.49

	Nine Months Ended
(In thousands, except share and per share amounts)	September 30, 2012			September 30, 2011
Net (loss) income attributable to Molycorp stockholders	$	(89,976	)	$	90,947
Dividends on Convertible Preferred Stock	(8,539		)	(7,116		)
(Loss) income attributable to common stockholders	(98,515		)	83,831
Weighted average common shares outstanding—basic	101,147,638			83,321,816
Basic (loss) earnings per share	$	(0.97	)	$	1.01
(Loss) income attributable to common stockholders	(98,515		)	83,831
Effect of dilutive 3.25% Convertible Notes	—			413
(Loss) income attributable to common stockholders adjusted for effect of dilution	(98,515		)	84,244
Weighted average common shares outstanding—diluted	101,147,638			84,596,676
Diluted (loss) earnings per share	$	(0.97	)	$	1.00

Diluted earnings per share reflect the dilutive impact of potential common stock and unvested restricted shares of common stock in the weighted average number of common shares outstanding during the period, if dilutive. For this purpose, the “treasury stock method” and “if-converted method,” as applicable, are used.

Under the treasury stock method, assumed proceeds upon the exercise of stock options are considered to be used to purchase common stock at the average market price of the shares during the period. Also under the treasury stock method, fixed awards and nonvested shares, such as restricted stock units, are deemed options for purposes of computing diluted earnings per share. At September 30, 2012 and 2011, all potential common stock under the treasury stock method were antidilutive in nature; consequently, the Company did not have any adjustments between earnings per share and diluted earnings per share related to stock options and restricted stock units.

In applying the if-converted method, conversion is not assumed for purposes of computing diluted earnings per share if the effect would be antidilutive. Convertible preferred stock (such as the Convertible Preferred Stock) is antidilutive whenever the amount of the dividend declared in or accumulated for the current period per common share obtainable on conversion, including the deemed dividend in the period from a beneficial conversion feature, exceeds basic earnings per share. The Convertible Preferred Stock was antidilutive at September 30, 2012 and 2011.

Also, under the if-converted method, convertible debt (such as the 3.25% Convertible Notes and the 6.00% Convertible Notes) is antidilutive whenever its interest per common share obtainable on conversion, including any deemed interest from a beneficial conversion feature and nondiscretionary adjustments, net of tax, exceeds basic earnings per share. At

24

September 30, 2012, the 3.25% Convertible Notes and the 6.00% Convertible Notes were antidilutive. The 3.25% Convertible Notes were dilutive for the three and nine months ended September 30, 2011. Therefore, the shares of common stock obtainable on the assumed conversion of the 3.25% Convertible Notes, the interest expense and the amortization of discount, net of income tax, were included in the computation of diluted earnings per share for the corresponding periods.

(18) Stock-Based Compensation

Starting in the first quarter of 2012, the Company granted performance-based restricted stock units ("PBRSUs") and restricted stock units (“RSUs”) to its executive officers, to certain other employees and to some non-employee directors of the Company under its 2010 Equity and Performance Incentive Plan. The RSUs vest on the third anniversary of the grant date. The grant-date fair value of RSUs is determined using the Company’s common stock price on the date of grant and is recognized as stock-based compensation expense on a straight-line basis over the three-year vesting period for the awards that are expected to vest. The PBRSUs vest with respect to between 0% and 150% of the PBRSUs granted to an individual on the basis of the achievement of certain management objectives measured by specified levels of total shareholder return relative to a defined index group over the performance period from January 1, 2012 through December 31, 2014, or upon the occurrence of certain change of control or termination events. The grant-date fair value of PBRSUs is determined using a lattice approach that incorporates a Monte Carlo simulation model. The compensation cost associated with the PBRSUs is recognized straight-line over the performance period for the awards that are expected to vest, even if the market conditions are never satisfied.

From January 1, 2012 through September 30, 2012, the Company issued 46,036 PBRSUs to certain employees, and a total of 235,474 RSUs to certain employees and non-employee directors of the Company.

Some of the RSUs granted to the non-employee directors relate to the grantees' election to convert a portion of their quarterly cash retainer into RSUs. These converted RSUs are fully vested because they relate to services already rendered by the non-employee directors. The same non-employee directors who elected to convert their cash retainer into RSUs, received additional RSUs as matching contributions by the Company equal to 25% of the converted units. The matching RSUs vest on the third anniversary of the grant date.

Also included in the RSUs issued during the first quarter of 2012 were grants related to the election by certain executive officers and other employees of the Company to convert a portion of their 2011 annual cash bonuses into RSUs. These RSUs are fully vested because they relate to services already rendered by the grantees. The conversion of the 2011 annual bonuses into RSUs resulted into an increase in Additional Paid-In Capital of $0.6 million in the first quarter of 2012. The same executive officers and other employees received additional RSUs as matching contribution by the Company equal to 25% of the converted RSUs. The matching RSUs vest on the third anniversary of the grant date.

The following tables summarize the activity related to stock-based awards from January 1, 2012 through September 30, 2012:

PBRSUs	Number of Shares		Weighted Average Grant-Date Fair Value
Unvested at January 1, 2012	—		—
Granted	46,036		$	30.30
Forfeited	(460	)	30.33
Vested	—		—
Unvested at September 30, 2012	45,576		$	30.30

RSUs	Number of Shares		Weighted Average Grant-Date Fair Value
Unvested at January 1, 2012	78,544		$	56.55
Granted	235,474		$	24.36
Forfeited	(4,135	)	39.26
Vested*	(24,764	)	$	26.67
Unvested at September 30, 2012	285,119		$	32.81

25

* Represents deferral and conversion of a portion of fees payable to certain non-employee directors of the Company, and deferral and conversion of a portion of the 2011 annual cash bonuses paid to certain executive officers and other employees of the Company.

RSAs	Number of Shares		Weighted Average Grant-Date Fair Value
Unvested at January 1, 2012	48,924		$	40.20
Granted	—		—
Forfeited	(601	)	$	48.87
Vested	—		—
Unvested at September 30, 2012	48,323		$	40.09

The following tables summarize the activity related to stock options during the first three quarters of 2012:

	September 30, 2012
Stock Options	Number of Shares	Weighted Average Exercise Price
Outstanding at January 1, 2012	52,819	$	48.87
Granted	—	—
Exercised	—	—
Forfeited and expired	—	—
Outstanding at September 30, 2012	52,819	$	48.87
Options exercisable at September 30, 2012	17,606	$	48.87

The stock-based compensation associated with all equity awards was $1.0 million and $2.9 million for the three and nine months ended September 30, 2012, respectively, and $0.6 million and $4.0 million for the three and nine months ended September 30, 2011, respectively.

(19) Commitments and Contingencies

(a) Future Operating Lease Commitments

The Company has certain operating leases for office space, trailers and certain equipment. Remaining annual minimum payments under these leases at September 30, 2012 were as follows:

(In thousands)	Total		Less Than 1 Year		1 - 3 Years		4 - 5 Years		More Than 5 Years
Operating lease obligations	$	9,826	$	1,417	$	5,929	$	1,110	$	1,370

(b) Purchase Commitments

In connection with the Molycorp Mountain Pass facility modernization and expansion and future operations, the Company entered into contractual commitments for the purchase of materials and services from various vendors. As a result of the Molycorp Canada acquisition, the Company assumed other purchase obligations totaling $6.3 million at September 30, 2012, which are expected to be settled between 2012 and 2014. Future payments for all purchase commitments at September 30, 2012 were as follows:

(In thousands)	Total		Less Than 1 Year		1 - 3 Years		4 - 5 Years		More Than 5 Years
Purchase obligations and other commitment	$	287,819	$	284,534	$	1,798	$	538	$	949

26

(c) Potential Environmental Obligations

As part of its ongoing remediation efforts at the Molycorp Mountain Pass facility, the Company identified liner defects in three of the onsite evaporation ponds in 2011. These defects led to minor groundwater contamination issues that are limited to a small area directly underneath the evaporation ponds. In order to remediate this issue, the Company will replace the primary lining system and might have to install a groundwater recovery system. The Company estimated the cost of these items at between $2.4 million and $4.6 million, which will be treated as capital expenditures and are included in the purchase obligations table above. The Company is in the process of finalizing the remediation plans with the Regional Water Quality Control Board.

(d) Labor Contract

Certain Molycorp Mountain Pass facility employees are covered by a collective bargaining agreement with the United Steelworkers of America that expires on March 15, 2015. At September 30, 2012, 226 employees, or approximately 60% of the Company’s workforce at the Molycorp Mountain Pass facility, were covered by this collective bargaining agreement.

At September 30, 2012, 172 employees, or approximately 29% of the workforce at the Company’s Molycorp Silmet facility, were unionized employees. The contract with the labor union in Estonia was renewed in February 2012.

(e) Reclamation Surety Bonds

At September 30, 2012, Molycorp had placed $28.8 million of surety bonds with California state and regional agencies to secure its Mountain Pass facility closure and reclamation obligations.

(f) Purported Class Action, Derivative Lawsuits and Investigation

In February 2012, a purported class action lawsuit captioned, Angelo Albano, Individually and on Behalf of All Others Similarly Situated v. Molycorp, Inc., et al., was filed against the Company and certain of its executive officers in the U.S. District Court for the District of Colorado. This federal court action alleges, among other things, that the Company and those officers violated Section 10(b) of the Securities Exchange Act of 1934 in connection with statements relating to its third quarter fiscal 2011 financial results and fourth quarter 2011 production guidance that the Company had filed with or furnished to the SEC, or otherwise made available to the public. In July 2012, the plaintiffs filed an amended consolidated class action complaint against the Company, certain of its officers and directors, certain of its private equity investors, and certain underwriters involved in our public offerings in 2011. The amended complaint alleges, among other things, that some or all of the defendants violated Sections 10(b), 20(a) and 20A of the Securities Exchange Act of 1934 as well as Sections 11, 12(a)(2) and 15 of the Securities Act of 1933. The plaintiffs are seeking unspecified damages and other relief. In October 2012, the defendants filed a motion to dismiss all the claims in the amended complaint. The Company believes the allegations are without merit and that it has valid defenses to such allegations. The Company intends to defend this action vigorously. The Company is unable to provide meaningful quantification of how the final resolution of these claims may impact its future consolidated financial position or results of operations.

Seven stockholder derivative lawsuits have been filed in three different jurisdictions purportedly on behalf of Molycorp, Inc., against certain of its directors and officers, and certain of its private equity investors. These cases have been filed in the Delaware Court of Chancery, the U.S. District Court in Colorado, and the District Court in Arapahoe County, Colorado. They are captioned: Gaines v. Smith et al., Case No. 7282 (Del. Ch. Feb. 12, 2012); Paskowitz v. Smith et al., Case No. 7319 (Del. Ch. Mar. 9, 2012); Wilson v. Smith et al., No. 7395-VCN (Del. Ch. April 4, 2012); Wells v. Smith et al., No. 1:12-cv-00447-WJM (D. Colo. Feb. 21, 2012); Swaggerty v. Smith et al., No. 12-cv-00589-CMA-KLM (D. Colo. Mar. 7, 2012); Clem v. Smith et al., No. 12 CV 392 (Arapahoe Cnty., Colo. Feb. 24, 2012); and Nationwide Consulting, Inc. v. Smith et al., No. 12 CV 448 (Arapahoe Cnty., Colo. Mar. 5, 2012). The Clem and Nationwide cases, which were previously consolidated under the caption Clem v. Smith et al., No. 12 CV 392 (Arapahoe Cnty., Colo.), have been voluntarily dismissed without prejudice. The Wells and Swaggerty cases have both been dismissed without prejudice in favor of the lawsuits proceeding in the Delaware Court of Chancery. As a result, plaintiffs in the Wells and Swaggerty cases filed notices of appeal before the 10th Circuit. The defendants have filed a responsive brief in the 10th Circuit in the Wells and Swaggerty cases. The 10th Circuit case has been fully briefed by the parties.

27

The derivative cases have been consolidated and are proceeding in the Delaware Court of Chancery. In August 2012, a consolidated amended shareholder derivative complaint was filed with the Delaware Court of Chancery challenging, among other things, certain sales of stock by officers, directors and private equity firms, and certain Molycorp corporate acquisitions during 2011. The amended complaint asserts causes of action for: (1) alleged breaches of fiduciary duty, including the duties of loyalty and due care; (2) alleged breach of fiduciary duty not to trade on or misuse material non-public information; (3) alleged unjust enrichment; and (4) alleged aiding and abetting a breach of fiduciary duty against controlling stockholders. On behalf of Molycorp, the plaintiffs in the derivative actions seek, among other things, monetary damages, restitution, an accounting, and certain changes to corporate governance procedures.

On October 22, 2012, the defendants filed motions to dismiss and motions to stay the derivative case with the Delaware Court of Chancery. Defendants filed their opening briefs in support of the Motions to Stay on November 5, 2012. The parties agreed that all briefing on defendants' Motions to Dismiss should be stayed pending resolution of defendants' Motions to Stay.

In August 2012, the staff of the SEC notified the Company that a formal order of investigation had been issued regarding, among other things, the accuracy of the Company's public disclosures. The Company is cooperating with the staff of the SEC in connection with the investigation. The Company cannot predict the length, scope or results of the investigation or the impact, if any, of the investigation on the Company's results of operations.

(20) Concentrations

(a) Products

Percentages of the Resources segment's sales by product that accounted for more than 10% of consolidated sales for the three and nine months ended September 30, 2012 and 2011, respectively, were approximately as follows:

	Three Months Ended September 30, 2012	Nine Months Ended September 30, 2012
Didymium, Neodymium and Praseodymium products	nm	10	%

	Three Months Ended September 30, 2011		Nine Months Ended September 30, 2011
Lanthanum products	29	%	25	%
Cerium products	nm		12	%
Didymium, Neodymium and Praseodymium products	36	%	29	%

nm = not material

The Chemicals and Oxides segment includes sales of REO, zirconium-based engineered materials and mixed rare earth/zirconium oxides from the Molycorp Canada acquisition on June 11, 2012, and REO from the Molycorp Silmet acquisition on April 1, 2011. For the three months ended September 30, 2012, sales by product from the Chemicals and Oxides segment that accounted for more than 10% of consolidated sales were approximately as follows:

	Three Months Ended September 30, 2012		Nine Months Ended September 30, 2012
Cerium products	16	%	11	%
Didymium products	12	%	nm

28

Within the Magnetic Materials and Alloys segment, sales of Neo Powders were approximately 34% and 22% of consolidated sales for the three months ended September 30, 2012 and for the period from June 12, 2012 to September 30, 2012, respectively. The Neo Powders were introduced into Molycorp's product mix with the Molycorp Canada acquisition.    

(b) Customers

For the quarter ended September 30, 2011, sales from the Resources segment to two of its customers in excess of 10% of consolidated sales were $38.4 million, and $14.7 million, respectively. For the nine months ended September 30, 2011, Resources’ sales to two of its customers in excess of 10% of consolidated sales were $62.5 million and $30.5 million, respectively.     

(21) Related-Party Transactions

Transactions with Traxys North America LLC

The Company made principal payments of $0 million and $3.1 million for the nine month period ended September 30, 2012 and for the year ended December 31, 2011, respectively, under the inventory financing arrangement with Traxys North America LLC (“Traxys and affiliates”), a subsidiary of one of the Company’s stockholders, Traxys S.a.r.l. The outstanding amounts payable to Traxys and affiliates under this arrangement were $0 and $0.9 million reported under Other current liabilities on the condensed consolidated balance sheet at September 30, 2012 and December 31, 2011, respectively. Molycorp also had outstanding amounts payable to Traxys and affiliates under the same arrangement of $0 and $2.8 million reported in Trade accounts payable at September 30, 2012 and December 31, 2011, respectively, associated with product purchased from Traxys and affiliates in 2011. For the three and nine months ended September 30, 2011, the Company made purchases of lanthanum oxide from Traxys and affiliates in the amount of $1.9 million and $6.2 million, respectively.

The Company and Traxys and affiliates also jointly market and sell certain lanthanum oxide, cerium oxide, misch metal and erbium oxide products. Pursuant to the terms of this other arrangement, the Company and Traxys and affiliates split gross margin equally once all costs associated with the sale are recovered by both parties. The Company had an outstanding related party receivable from Traxys and affiliates in the amount of $0 million and $0.2 million at September 30, 2012 and December 31, 2011, respectively.

At September 30, 2012 and December 31, 2011, Molycorp had also a balance receivable from Traxys and affiliates of $0 million and $2.1 million, respectively, related to sales of tantalum metal to Traxys and affiliates of $3.2 million in 2011.

Transactions with Neo Material Technologies Inc.

During the period from January 1, 2012 to June 11, 2012, Molycorp sold neodymium/ praseodymium oxides for $4.3 million and heavy rare earths for $1.6 million to Neo Material Technologies, Inc. There were no sales between the companies in the comparative 2011 period. The related intercompany accounts receivable and payable were eliminated in consolidation.

Transactions with equity method investees: TMT, Keli and Ingal Stade

The Company supplies Neo Powders to TMT to produce rare earth magnetic compounds. Molycorp then purchases these compounds back from TMT in its normal course of business. Additionally, Keli processes rare earth oxides into metals for inclusion in the Neo Powders.

During the third quarter of 2012 and for the period from June 12, 2012 to September 30, 2012, the Company sold $1.3 million and $1.4 million of Neo Powders to TMT, respectively, and purchased $1.4 million and $1.9 million worth of compounds from TMT during the same respective periods.

The Company purchased metals and received services from Keli amounting to $16.1 million and $21.4 million for the third quarter of 2012 and for the period from June 12, 2012 to September 30, 2012, respectively.

29

Ingal Stade sells gallium to the Company's facilities located in Ontario, Canada and to some of its facilities in the United States. For third quarter of 2012 and for the period from June 12, 2012 to September 30, 2012, the Company purchased $1.3 million and $1.7 million of gallium metal from Ingal Stade, respectively.

(22) Net Change in Operating Assets and Liabilities

Net change in operating assets and liabilities, net of the effects of acquisitions and dispositions, consists of the following:

	Nine Months Ended
(In thousands)	September 30, 2012			September 30, 2011
Decrease (increase) in operating assets:
Accounts receivable	$	88,997		$	(42,250	)
Inventory	13,202			(39,408		)
Prepaid expenses and other assets	7,174			(1,596		)
Increase (decrease) in operating liabilities:
Accounts payable	(43,223		)	(7,099		)
Income tax payable	(39,483		)	—
Interest payable	(9,704		)	—
Asset retirement obligation	—			(581		)
Accrued expenses	(49,044		)	2,245
	$	(32,081	)	$	(88,689	)

(23) Supplemental Cash Flow Information

	Nine Months Ended
(In thousands)	September 30, 2012		September 30, 2011
Non-cash financing activities and investing activities:
Change in accrued capital expenditures	$	48,182	$	61,783
Fixed assets additions under capital lease	$	15,658	$	—

(24) Research and Development

The Company invests significant resources to improve the efficiency of its REO processing operations, the development of new applications for individual rare earth elements and exploratory drilling. These costs consist primarily of salaries, outside labor, material and equipment.

(25) Derivative Instruments

The Company accounts for derivative instruments using the fair value method. GAAP provides for a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 inputs are quoted market prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted market prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for the asset or liability.

As a result of the Molycorp Canada acquisition, the Company assumed a liability associated with the put option issued to holders of the noncontrolling interest of Buss & Buss, a business acquired by Molycorp Canada's predecessor company. The Buss & Buss put option is related to a share purchase agreement (“SPA”) between NMT Holding GmbH, a German subsidiary of the Company, and the shareholders of Buss & Buss entered into May 27, 2010 by Molycorp Canada's predecessor company. The SPA includes a call and a put option on shares of the remaining shareholder and his legal successors. If the call option is exercised by the Company, a premium is added to the consideration to purchase the underlying shares in Buss & Buss. If the

30

put option is exercised by the remaining shareholder of Buss & Buss or his legal successors, a discount will reduce the cost basis of the securities sold to the Company. The Company does not account for this derivative as a hedge. The put option had a fair value of $8.8 million at September 30, 2012, recorded as Derivative liability in the condensed consolidated balance sheets. The change in fair value of the put option resulted in an unrealized loss of $0.4 million for the period from June 12, 2012 to September 30, 2012, which was recognized in Interest expense in the condensed consolidated statements of operations and comprehensive income.

The technique Molycorp used to fair value this derivative is the income approach based on a discounted cash flow model. With the exception of the risk free interest rate, the inputs used to fair value this put option are based on unobservable Level 3 inputs based on management's assumptions. These inputs include: equity-risk premium, risk premium, size premium and growth rate. Any reasonably foreseeable changes in assumed levels of unobservable inputs used to fair value this put option would not be expected to have a material impact on the Company's financial position or results of operations.

On March 28, 2012, the Company entered into a contingent forward contract to purchase Canadian dollars with a notional amount of Cdn$870.0 million to manage the foreign currency exposure with respect to its planned acquisition of Molycorp Canada. The Company did not apply hedge accounting to this contingent forward contract. Upon settlement of this derivative on June 11, 2012 (Molycorp Canada acquisition date), the Company recognized a loss of $37.5 million in Other expense. Of this loss, $6.7 million was recognized during the three months ended March 31, 2012 and the remainder during the second quarter of 2012.

(26) Pension

In accordance with the terms of the Arrangement Agreement, Molycorp maintained the terms of the benefit plan for Molycorp Canada’s current and former employees. Molycorp Canada's predecessor company had a defined benefit pension plan (“Pension Plan”), which covered all hourly employees employed as of September 30, 1995, and all hourly employees subsequently hired by Molycorp Canada's predecessor company up to 2003 at its former U.S. manufacturing facility in Anderson, Indiana. A December 31 measurement date is used for the Pension Plan. Molycorp paid $0.2 million as of September 30, 2012 of the estimated total contributions to the Pension Plan for 2012 of $0.2 million.

Molycorp also maintained the terms of Molycorp Canada postretirement medical and life insurance benefits plan for certain employees from the Anderson, Indiana manufacturing facility. The measurement date for this postretirement benefit plan (“PBP”) is December 31.

The actuarial valuation for funding purposes of the Pension Plan and PBP is January 1 of each year. The components of the net periodic pension expense for the period from June 12, 2012 to September 30, 2012 for the Pension Plan and PBP are set forth below (in thousands):

Pension Plan and PBP	For the period from June 12, 2012 to September 30, 2012
Components of net periodic benefit cost:
Service Cost	$	—
Interest cost	90
Expected return on assets	(67		)
Amortization of transition obligation/(asset)	—
Amortization of prior service cost	(1		)
Amortization of actuarial loss	55
Net periodic benefit cost	$	77

(27) Recent Accounting Pronouncements

In December 2011, the Financial Accounting Standard Board ("FASB") issued ASU 2011-12, Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in ASU 2011-05. ASU 2011-12 defers the requirement that companies present reclassification adjustments for each component of Accumulated Other Comprehensive Income (“AOCI”) in both net income and other comprehensive income on the face of the financial statements. Companies will continue to be required to present amounts reclassified out of AOCI on the face of the

31

financial statements or disclose those amounts in the notes to the financial statements. During the deferral period, there is no requirement to separately present or disclose the reclassification adjustments into net income. For the period ended September 30, 2012, the Company did not have any reclassification adjustments for components of AOCI.

In September 2011, the FASB issued ASU 2011-08, Testing Goodwill for Impairment. Under this updated guidance, an entity will have the option to first assess qualitatively whether it is necessary to perform the current two-step goodwill impairment test. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test is required. Otherwise, no further testing is necessary. The update does not change how an entity performs the two-step impairment test under the current guidance. This ASU is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011. Early adoption is permitted. The Company does not expect the adoption of this updated guidance to have a significant impact on its financial statements.

(28) Subsequent Events

Preferred stock dividend

In November 2012, the Company declared a cash dividend of $1.375 per share on the Convertible Preferred Stock to be paid on December 1, 2012 to holders of record at the close of business on November 15, 2012.

32

(29) Subsidiary Guarantor Financial Information

The Senior Notes are jointly, severally and unconditionally guaranteed by all of Molycorp, Inc.'s existing and future domestic material subsidiaries, as defined in the indenture governing the Senior Notes. The Senior Notes guarantee of a guarantor will automatically terminate, and the obligations of such guarantor under the Senior Notes guarantee will be unconditionally released and discharged, upon (all terms as defined in the indenture governing the Senior Notes):

(1) any sale, exchange, transfer or other disposition of a majority of the capital stock of (including by way of consolidation or merger) such guarantor by Molycorp or any restricted subsidiary to any person or persons, as a result of which such guarantor is no longer a direct or indirect subsidiary of Molycorp;

(2) any sale, exchange, transfer or other disposition of all or substantially all assets of such guarantor that results in such guarantor having no assets;

(3) the designation by Molycorp of such guarantor as an unrestricted subsidiary; or

(4) defeasance or discharge of the Senior Notes;

provided that any such event occurs in accordance with all other applicable provisions of the indenture.

Presented below are the condensed consolidating financial statements of Molycorp, Inc. (“Parent”) as issuer, its combined guarantor subsidiaries and its combined non-guarantor subsidiaries, which are presented as an alternative to providing separate financial statements for the guarantors. The accounts of the Parent, the guarantor and non-guarantor subsidiaries are presented using the equity method of accounting for investments in subsidiaries for purposes of these condensed consolidating financial statements only. Certain of the prior periods separate financial information has been reclassified to conform to the presentation of the most recent interim period disclosed.

	At September 30, 2012
	(in thousands)
Condensed Consolidating Balance Sheets	Parent		Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Eliminations			Molycorp, Inc. consolidated
Current assets:
Cash and cash equivalents	$	175,400	$	3,830	$	256,795		$	—		$	436,025
Trade accounts receivable, net	—		13,644		74,827			—			88,471
Inventory	—		48,335		232,798			—			281,133
Deferred charges	—		4,589		7,928			—			12,517
Deferred tax assets	—		2,049		15,353			—			17,402
Income tax receivable	—		38,933		—			—			38,933
Prepaid expenses and other current assets	—		20,867		27,844			—			48,711
Total current assets	175,400		132,247		615,545			—			923,192
Non-current assets:
Deposits	1,752		21,362		173			—			23,287
Property, plant and equipment, net	—		1,223,557		139,887			—			1,363,444
Inventory	—		9,601		—			—			9,601
Intangible assets, net	—		524		478,649			—			479,173
Investments	—		46,900		21,106			—			68,006
Deferred tax assets	—		21,002		(10,704		)	—			10,298
Goodwill	—		1,977		503,026			—			505,003
Investments in consolidated subsidiaries	932,310		95,131		—			(1,027,441		)	—
Intercompany accounts receivable	1,680,993		156,646		—			(1,837,639		)	—

33

Other non-current assets	—			817			4,505			—			5,322
Total non-current assets	2,615,055			1,577,517			1,136,642			(2,865,080		)	2,464,134
Total assets	$	2,790,455		$	1,709,764		$	1,752,187		$	(2,865,080	)	$	3,387,326
Current liabilities:
Trade accounts payable	$	—		$	185,097		$	45,158		$	—		$	230,255
Accrued expenses	27,733			8,030			30,526			—			66,289
Income tax payable	—			63			25,538			—			25,601
Deferred tax liabilities	—			—			128			—			128
Debt and capital lease obligations	—			242			32,693			—			32,935
Other current liabilities	—			2,096			—			—			2,096
Total current liabilities	27,733			195,528			134,043			—			357,304
Non-current liabilities:
Asset retirement obligation	—			20,727			—			—			20,727
Deferred tax liabilities	(94		)	43,997			145,991			—			189,894
Debt and capital lease obligations	1,160,994			15,324			7,210			—			1,183,528
Derivative liability	—			—			8,846			—			8,846
Pension liabilities	—			—			2,855			—			2,855
Intercompany accounts payable	—			1,351,099			486,540			(1,837,639		)	—
Other non-current liabilities	—			1,061			1,959			—			3,020
Total non-current liabilities	1,160,900			1,432,208			653,401			(1,837,639		)	1,408,870
Total liabilities	$	1,188,633		$	1,627,736		$	787,444		$	(1,837,639	)	$	1,766,174
Stockholders’ equity:
Common stock	138			—			—			—			138
Preferred stock	2			—			—			—			2
Additional paid-in capital	1,686,226			149,857			947,376			(1,097,233		)	1,686,226
Accumulated other comprehensive loss	(9,646		)	—			(9,646		)	9,646			(9,646		)
(Deficit) retained earnings	(74,898		)	(67,829		)	7,683			60,146			(74,898		)
Total Molycorp stockholders’ equity	1,601,822			82,028			945,413			(1,027,441		)	1,601,822
Noncontrolling interests	—			—			19,330			—			19,330
Total stockholders’ equity	1,601,822			82,028			964,743			(1,027,441		)	1,621,152
Total liabilities and stockholders’ equity	$	2,790,455		$	1,709,764		$	1,752,187		$	(2,865,080	)	$	3,387,326

	At December 31, 2011
	(in thousands)
Condensed Consolidating Balance Sheets	Parent		Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Eliminations		Molycorp, Inc. consolidated
Current assets:
Cash and cash equivalents	$	407,446	$	10,758	$	651	$	—	$	418,855
Trade accounts receivable, net	—		58,619		12,060		—		70,679
Inventory	—		52,246		59,697		—		111,943
Deferred charges	—		7,318		—		—		7,318
Prepaid income taxes	—		10,514		—		—		10,514

34

Prepaid expenses and other current assets	—			17,845		1,890			—			19,735
Total current assets	407,446			157,300		74,298			—			639,044
Non-current assets:
Deposits	1,751			21,362		173			—			23,286
Property, plant and equipment, net	—			500,612		61,016			—			561,628
Inventory	—			4,362		—			—			4,362
Intangible assets, net	—			573		2,499			—			3,072
Investments	—			20,000		—			—			20,000
Goodwill	—			1,977		1,455			—			3,432
Investments in consolidated subsidiaries	150,510			118,879		—			(269,389		)	—
Intercompany accounts receivable	476,711			25,870		—			(502,581		)	—
Other non-current assets	—			301		—			—			301
Total non-current assets	628,972			693,936		65,143			(771,970		)	616,081
Total assets	$	1,036,418		$	851,236	$	139,441		$	(771,970	)	$	1,255,125
Current liabilities:
Trade accounts payable	$	—		$	139,408	$	22,179		$	—		$	161,587
Accrued expenses	311			11,072		1,515			—			12,898
Deferred tax liabilities	—			1,356		—			—			1,356
Debt	—			—		1,516			—			1,516
Short-term borrowings-related party	—			870		—			—			870
Current portion of asset retirement obligation	—			396		—			—			396
Total current liabilities	311			153,102		25,210			—			178,623
Non-current liabilities:
Asset retirement obligation	—			15,145		—			—			15,145
Deferred tax liabilities	—			18,899		—			—			18,899
Debt	190,877			—		5,668			—			196,545
Intercompany accounts payable	—			489,180		13,401			(502,581		)	—
Other non-current liabilities	—			683		—			—			683
Total non-current liabilities	190,877			523,907		19,069			(502,581		)	231,272
Total liabilities	$	191,188		$	677,009	$	44,279		$	(502,581	)	$	409,895
Stockholders’ equity:
Common stock	84			—		—			—			84
Preferred stock	2			—		—			—			2
Additional paid-in capital	838,547			149,857		91,158			(241,015		)	838,547
Accumulated other comprehensive loss	(8,481		)	—		(8,481		)	8,481			(8,481		)
Retained earnings	15,078			24,370		12,485			(36,855		)	15,078
Total stockholders’ equity	845,230			174,227		95,162			(269,389		)	845,230
Total liabilities and stockholders’ equity	$	1,036,418		$	851,236	$	139,441		$	(771,970	)	$	1,255,125

35

	Three Months Ended September 30, 2012
	(in thousands)
Condensed Consolidating Statements of Operations and Comprehensive Income	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Molycorp, Inc. consolidated
Sales	$	—		$	26,103		$	192,060		$	(12,559	)	$	205,604
Costs of sales:
Costs excluding depreciation and amortization	—			(38,919		)	(157,768		)	12,559			(184,128		)
Depreciation and amortization	—			(3,375		)	(7,237		)	—			(10,612		)
Gross (loss) profit	—			(16,191		)	27,055			—			10,864
Operating expenses:
Selling, general and administrative	(29		)	(20,147		)	(11,292		)	—			(31,468		)
Corporate development	—			(1,073		)	—			—			(1,073		)
Depreciation, amortization and accretion	—			(742		)	(8,981		)	—			(9,723		)
Research and development	—			(2,497		)	(6,432		)	—			(8,929		)
Operating (loss) income	(29		)	(40,650		)	350			—			(40,329		)
Other (expense) income:
Other (expense) income	—			(68		)	11			—			(57		)
Foreign exchange (losses) gains, net	—			(3		)	1,913			—			1,910
Interest expense, net	(2,920		)	(1,076		)	(1,273		)	—			(5,269		)
Interest income (expense) from intercompany notes	453			(324		)	(129		)	—			—
Equity earnings from consolidated subsidiaries	(16,395		)	4,090			—			12,305			—
	(18,862		)	2,619			522			12,305			(3,416		)
Loss before income taxes and equity earnings	(18,891		)	(38,031		)	872			12,305			(43,745		)
Income tax (expense) benefit	—			23,537			5,419			—			28,956
Equity in results of affiliates	—			(682		)	20			—			(662		)
Net (loss) income	(18,891		)	(15,176		)	6,311			12,305			(15,451		)
Net income attributable to noncontrolling interest	—			—			(3,440		)	—			(3,440		)
Net (loss) income attributable to Molycorp stockholders	$	(18,891	)	$	(15,176	)	$	2,871		$	12,305		$	(18,891	)
Net (loss) income	$	(18,891	)	$	(15,176	)	$	6,311		$	12,305		$	(15,451	)
Other comprehensive income:
Foreign currency translation adjustments	—			—			526			—			526
Comprehensive (loss) income	$	(18,891	)	$	(15,176	)	$	6,837		$	12,305		$	(14,925	)
Comprehensive (loss) income attributable to:
Molycorp stockholders	(18,891		)	(15,176		)	10,277			12,305			(11,485		)
Noncontrolling interest	—			—			(3,440		)	—			(3,440		)
	$	(18,891	)	$	(15,176	)	$	6,837		$	12,305		$	(14,925	)

36

	Nine Months Ended September 30, 2012
	(in thousands)
Condensed Consolidating Statements of Operations and Comprehensive Income	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Molycorp, Inc. consolidated
Sales	$	—		$	121,172		$	293,794		$	(20,315	)	$	394,651
Costs of sales:
Costs excluding depreciation and amortization	—			(105,185		)	(252,899		)	20,315			(337,769		)
Depreciation and amortization	—			(7,539		)	(11,526		)	—			(19,065		)
Gross profit	—			8,448			29,369			—			37,817
Operating expenses:
Selling, general and administrative	45			(62,746		)	(16,020		)	—			(78,721		)
Corporate development	(46		)	(19,333		)	—			—			(19,379		)
Depreciation, amortization and accretion	—			(1,441		)	(10,920		)	—			(12,361		)
Research and development	—			(10,584		)	(8,044		)	—			(18,628		)
Operating (loss) income	(1		)	(85,656		)	(5,615		)	—			(91,272		)
Other (expense) income:
Other expense	—			(37,562		)	(53		)	—			(37,615		)
Foreign exchange (losses) gains, net	—			(5		)	729			—			724
Interest expense, net	(12,602		)	(194		)	(2,193		)	—			(14,989		)
Interest income (expense) from intercompany notes	1,326			(967		)	(359		)	—			—
Equity earnings from consolidated subsidiaries	(78,699		)	(18,302		)	—			97,001			—
	(89,975		)	(57,030		)	(1,876		)	97,001			(51,880		)
Loss before income taxes and equity earnings	(89,976		)	(142,686		)	(7,491		)	97,001			(143,152		)
Income tax benefit	—			51,962			6,480			—			58,442
Equity in results of affiliates	—			(1,475		)	329			—			(1,146		)
Net loss	(89,976		)	(92,199		)	(682		)	97,001			(85,856		)
Net income attributable to noncontrolling interest	—			—			(4,120		)	—			(4,120		)
Net loss attributable to Molycorp stockholders	$	(89,976	)	$	(92,199	)	$	(4,802	)	$	97,001		$	(89,976	)
Net loss	$	(89,976	)	$	(92,199	)	$	(682	)	$	97,001		$	(85,856	)
Other comprehensive income:
Foreign currency translation adjustments	—			—			(1,165		)	—			(1,165		)
Comprehensive loss	$	(89,976	)	$	(92,199	)	$	(1,847	)	$	97,001		$	(87,021	)
Comprehensive loss attributable to:
Molycorp stockholders	(89,976		)	(92,199		)	2,273			97,001			(82,901		)
Noncontrolling interest	—			—			(4,120		)	—			(4,120		)
	$	(89,976	)	$	(92,199	)	$	(1,847	)	$	97,001		$	(87,021	)

37

	Three Months Ended September 30, 2011
	(in thousands)
Condensed Consolidating Statements of Operations and Comprehensive Income	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Molycorp, Inc. consolidated
Sales	$	—		$	139,326		$	35,910		$	(37,186	)	$	138,050
Costs of sales:
Costs excluding depreciation and amortization	—			(62,259		)	(25,529		)	37,186			(50,602		)
Depreciation and amortization	—			(2,440		)	(2,616		)	—			(5,056		)
Gross profit	—			74,627			7,765			—			82,392
Operating expenses:
Selling, general and administrative	(592		)	(11,374		)	(216		)	—			(12,182		)
Corporate development	—			(573		)	—			—			(573		)
Depreciation, amortization and accretion	—			(148		)	(396		)	—			(544		)
Research and development	—			(2,148		)	—			—			(2,148		)
Operating (loss) income	(592		)	60,384			7,153			—			66,945
Other (expense) income:
Other expense	—			(117		)	—			—			(117		)
Foreign exchange losses, net	—			—			(2,000		)	—			(2,000		)
Interest expense, net	(599		)	(11		)	(61		)	—			(671		)
Interest income (expense) from intercompany notes	61			(24		)	(37		)	—			—
Equity earnings from consolidated subsidiaries	46,486			5,309			—			(51,795		)	—
	45,948			5,157			(2,098		)	(51,795		)	(2,788		)
Income (loss) before income taxes	45,356			65,541			5,055			(51,795		)	64,157
Income tax expense	—			(19,055		)	(1		)	—			(19,056		)
Net income (loss)	45,356			46,486			5,054			(51,795		)	45,101
Net income attributable to noncontrolling interest	—			—			255			—			255
Net income (loss) attributable to Molycorp stockholders	$	45,356		$	46,486		$	5,309		$	(51,795	)	$	45,356
Net income (loss)	$	45,356		$	46,486		$	5,054		$	(51,795	)	$	45,101
Other comprehensive income:
Foreign currency translation adjustments	—			—			(5,564		)	—			(5,564		)
Comprehensive income (loss)	$	45,356		$	46,486		$	(510	)	$	(51,795	)	$	39,537
Comprehensive income (loss) attributable to:
Molycorp stockholders	45,356			46,486			299			(51,795		)	40,346
Noncontrolling interest	—			—			(809		)	—			(809		)
	$	45,356		$	46,486		$	(510	)	$	(51,795	)	$	39,537

38

	Nine Months Ended September 30, 2011
	(in thousands)
Condensed Consolidating Statements of Operations and Comprehensive Income	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Molycorp, Inc. consolidated
Sales	$	—		$	252,132		$	68,568		$	(56,773	)	$	263,927
Costs of sales:
Costs excluding depreciation and amortization	—			(115,622		)	(46,821		)	56,773			(105,670		)
Depreciation and amortization	—			(6,820		)	(2,768		)	—			(9,588		)
Gross profit	—			129,690			18,979			—			148,669
Operating expenses:
Selling, general and administrative	(3,903		)	(25,784		)	(1,778		)	—			(31,465		)
Corporate development	—			(3,889		)	—			—			(3,889		)
Depreciation, amortization and accretion	—			(988		)	(396		)	—			(1,384		)
Research and development	—			(5,165		)	—			—			(5,165		)
Operating loss	(3,903		)	93,864			16,805			—			106,766
Other (expense) income:
Other expense	—			(152		)	—			—			(152		)
Foreign exchange losses, net	—			—			(1,850		)	—			(1,850		)
Interest expense, net	(295		)	(3		)	(163		)	—			(461		)
Interest income (expense) from intercompany notes	61			(24		)	(37		)	—			—
Equity earnings from consolidated subsidiaries	95,084			14,041			—			(109,125		)	—
	94,850			13,862			(2,050		)	(109,125		)	(2,463		)
Income before income taxes	90,947			107,726			14,755			(109,125		)	104,303
Income tax expense	—			(12,642		)	(1		)	—			(12,643		)
Net income	90,947			95,084			14,754			(109,125		)	91,660
Net income attributable to noncontrolling interest	—			—			(713		)	—			(713		)
Net income attributable to Molycorp stockholders	$	90,947		$	95,084		$	14,041		$	(109,125	)	$	90,947
Net income	$	90,947		$	95,084		$	14,754		$	(109,125	)	$	91,660
Other comprehensive income:
Foreign currency translation adjustments	—			—			(4,240		)	—			(4,240		)
Comprehensive income	$	90,947		$	95,084		$	10,514		$	(109,125	)	$	87,420
Comprehensive income attributable to:
Molycorp stockholders	90,947			95,084			10,224			(109,125		)	87,130
Noncontrolling interest	—			—			290			—			290
	$	90,947		$	95,084		$	10,514		$	(109,125	)	$	87,420

39

	Nine Months Ended September 30, 2012
	(in thousands)
Condensed Consolidating Statements of Cash Flows	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Molycorp, Inc. consolidated
Net cash (used in) provided by operating activities	17,094			(95,576		)	31,294			—			(47,188		)
Cash flows from investing activities:
Cash paid in connection with acquisitions, net of cash acquired	—			—			(591,011		)	—			(591,011		)
Loans to subsidiaries	(683,063		)	—			—			683,063			—
Net intercompany advances and repayments	(792,709		)	680,966			111,743			—			—
Repayments from subsidiaries	34,327			—			—			(34,327		)	—
Investment in subsidiaries	(350,000		)	—			—			350,000			—
Notes receivable to non-guarantor	—			(227,512		)	—			227,512			—
Repayments of notes receivable from non-guarantor	—			100,000			—			(100,000		)	—
Investment in joint venture				(28,130		)	—			—			(28,130		)
Deposits	—			(516		)	—			—			(516		)
Capital expenditures	—			(628,407		)	(16,276		)	—			(644,683		)
Other investing activities	—			—			4,953			—			4,953
Net cash (used in) provided by investing activities	(1,791,445		)	(103,599		)	(490,591		)	1,126,248			(1,259,387		)
Cash flows provided from financing activities:
Capital contributions from stockholder	390,225			—			—			—			390,225
Capital contribution from Parent	—			—			350,000			(350,000		)	—
Repayments of debt	—			(870		)	(227,561		)	—			(228,431		)
Net proceeds from sale of common stock	132,471			—			—			—			132,471
Issuance of 10% Senior Secured Notes	635,373			—			—			—			635,373
Issuance of 6.00% Convertible Notes	395,712			—			—			—			395,712
Payments of preferred dividends	(8,539		)	—			—			—			(8,539		)
Proceeds from debt	—			—			9,456			—			9,456
Borrowings from parent	—			227,512			455,551			(683,063		)	—
Repayments to parent	—			(34,327		)	—			34,327			—
Notes receivable from guarantor	—			—			227,512			(227,512		)	—
Repayments of notes receivable from guarantor	—			—			(100,000		)	100,000			—
Other financing activities	(2,937		)	(68		)	(326		)	—			(3,331		)
Net cash provided by (used in) financing activities	1,542,305			192,247			714,632			(1,126,248		)	1,322,936
Effect of exchange rate changes on cash	—			—			809			—			809
Net change in cash and cash equivalents	(232,046		)	(6,928		)	256,144			—			17,170
Cash and cash equivalents at beginning of the period	407,446			10,758			651			—			418,855
Cash and cash equivalents at end of period	$	175,400		$	3,830		$	256,795		$	—		$	436,025

40

	Nine Months Ended September 30, 2011
	(in thousands)
Condensed Consolidating Statements of Cash Flows	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Molycorp, Inc. consolidated
Net cash (used in) provided by operating activities	(1,957		)	28,085			2,596			—			28,724
Cash flows from investing activities:
Cash paid in connection with acquisitions, net of cash acquired	—			(20,126		)	105			—			(20,021		)
Cash paid to acquire non-marketable securities	—			(20,000		)	—			—			(20,000		)
Loans to subsidiaries	(20,161		)	—			—			20,161			—
Net intercompany advances and repayments	(179,699		)	180,374			(675		)	—			—
Deposits	16,449			(13,503		)	—			—			2,946
Capital expenditures	—			(157,037		)	(3,880		)	—			(160,917		)
Other investing activities	—			—			19			—			19
Net cash used in investing activities	(183,411		)	(30,292		)	(4,431		)	20,161			(197,973		)
Cash flows provided from financing activities:
Repayments of short-term borrowings—related party	—			(2,343		)	—			—			(2,343		)
Repayments of debt	—			—			(5,447		)	—			(5,447		)
Net borrowing from parent	—			8,124			12,037			(20,161		)	—
Net proceeds from sale of preferred stock	199,642			—			—			—			199,642
Net proceeds from sale of Convertible Notes	223,100			—			—			—			223,100
Payments of preferred dividends	(6,167		)	—			—			—			(6,167		)
Proceeds from debt	—			—			6,337			—			6,337
Net cash provided by financing activities	416,575			5,781			12,927			(20,161		)	415,122
Effect of exchange rate changes on cash	—			—			(348		)	—			(348		)
Net change in cash and cash equivalents	231,207			3,574			10,744			—			245,525
Cash and cash equivalents at beginning of the period	316,430			—			—			—			316,430
Cash and cash equivalents at end of period	$	547,637		$	3,574		$	10,744		$	—		$	561,955

41